Utilization of dietary lipids requires that they first be absorbed through the intestine. As these molecules are oils they would essentially be insoluble in the aqueous intestinal environment. Solubilization (emulsification) of dietary lipid is accomplished, initially, via the agitation action as food passes through the stomach and then the emuslification process continues within the intestine via interaction with the bile salts that are synthesized in the liver and secreted from the gallbladder.
Dietary lipids, in the form of triglycerides (triacylglycerides), phospholipids, and cholesterol, are digested by various lipases. The bulk of dietary lipids in the human diet are in the form of triglycerides. The lipases found in the gastrointestinal tract include one originally identified as lingual lipase (secreted by acinar cells of von Ebner glands of the tongue), gastric lipase (secreted by Chief cells of the stomach), pancreatic lipase (PNLIP gene), and pancreatic lipase-related protein 2 (PNLIPRP2 gene). These enzymes generate free fatty acids and a mixture of mono- and diglycerides from dietary triglycerides.
Lingual lipase and gastric lipase are both derived from the lipase F, gastric (LIPF) gene and together constitute the acid lipases. The acidic lipases function essentially only in the acidic environment of the stomach. However, evidence suggests that lingual lipase functions within the mouth allowing for the ability to taste non-esterified fatty acids (NEFAs). The acid lipases are distinct from pancreatic lipases in that they do not require a lipid-bile acid interface for activity nor do they require the presence of the accessory protein, colipase.
Pancreatic lipases, on the other hand, only function in the neutral pH environment generated in the small intestine by the secretion of pancreatic bicarbonate (HCO3–). Also, pancreatic lipases require the presence of colipase and a lipid-bile acid interface for their activity. The role of colipase in pancreatic lipase function is to anchor the lipase to the surface of an emulsified lipid droplet and to prevent it from being removed by bile salts. Pancreatic lipase degrades triglycerides at the sn-1 and sn-3 positions sequentially to generate 1,2-diacylglycerides (DAG) and 2-monoacylglycerides (MAG). Phospholipids are degraded at the sn-2 position by pancreatic phospholipase A2 releasing a free fatty acid and the lysophospholipid.
Table of the Major Lipases of Lipid Digestion and Plasma Lipid Metabolism
|Lipase Name||Gene and Structure||Primary Source||Functions / Comments|
|carboxy ester lipase, CEL||CEL: 9q34.13; 11 exons||pancreas||encoded precursor protein is 756 amino acids; hydrolyzes cholesteryl esters, tri-, di-, and monoglycerides, phospholipids, lysophospholipids, and ceramides; primary site of synthesis is pancreas, also expressed in liver, intestine, and macrophages; participates in chylomicron assembly in intestinal enterocytes and their secretion|
|lysosomal acid lipase, LAL||LIPA: 10q23.31: 10 exons||lysosomes||enzyme is also called cholesterol ester hydrolase; three alternatively spliced mRNAs encode two distinct protein isoforms (399 and 283 amino acid precursor proteins); hydrolyzes cholesteryl esters and triglycerides|
|hepatic lipase||LIPC: 15q21.3; 15 exons||hepatocytes||encoded precursor protein is 499 amino acids; protein is secreted from hepatocytes and binds to heparan-sulfate proteoglycans (HSPG) on surface of hepatocytes and endothelial cells; released to plasma via interactions involving apoA-II-enriched HDL; major substrates are IDL and triglyceride-rich HDL; activity is inhibited by angiopoietin-like protein 3 (ANGPTL3)|
|hormone sensitive lipase, HSL||LIPE: 19q13.2; 15 exons||adipocytes; testis||initially described as an epinephrine- and glucagon-responsive gene encoding an adipose tissue triglyceride lipase; alternative 5′ exon utilization results in a short form (775 amino acids) and a long form (1076 amino acids) of the enzyme; the short form is exclusive to adipose tissue, the long form was originally identified as a testis-specific isoform; pancreatic β-cells utilize an alternative translational start site generating a protein of 818 amino acids; primary substrates in adipose tissue are diglycerides; known to hydrolyze triglycerides and monoglycerides (albeit inefficiently), and cholesteryl esters, as well as other lipid and water soluble substrates; activities detailed in the next section|
|gastric/lingual lipase||LIPF: 10q23.31; 11 exons||gastric Chief cells||four alternatively spliced mRNAs; four protein isoforms; acidic lipase responsible for hydrolysis of dietary triglycerides within the stomach|
|endothelial lipase||LIPG: 18q21.1; 12 exons||endothelial cells||two alternatively spliced mRNAs encoding two protein isoforms (500 and 426 amino acid precursor proteins); remains associated with endothelial cells; functions primarily as a phospholipase A1 (PLA1) type hydrolase with principal substrates being phosphatidylcholines; participates in HDL metabolism; activity inhibited by the hepatocyte-derived plasma protein, angiopoietin-like protein 3 (ANGPTL3)|
|lipoprotein lipase||LPL: 8p21.3; 10 exons||adipocytes, cardiac myocytes and skeletal muscle cells||475 amino acid precursor protein; primarily expressed in adipose tissue, skeletal muscle, and cardiac capillary endothelial cells; functions as a homodimeric enzyme; synthesized in cells of the tissues via the ER secretory pathway; transferred across the subendothelial spaces to capillary endothelial cells through interaction with endothelial cell glycosylphosphatidylinositol-anchored HDL binding protein 1 (GPIHBP1); LPL remains attached to endothelial cell surfaces through its interaction with GPIHBP1; primary substrates are triglyceride-rich chylomicrons and VLDL; activity inhibited by the hepatocyte-derived plasma protein, angiopoietin-like protein 3 (ANGPTL3) and by ANGPTL4|
|monoglyceride lipase||MGLL: 3q21.3; 13 exons||three alternatively spliced mRNAs encoding three protein isoforms; in addition to hydrolyzing monoglycerides, this serine hydrolase also metabolizes the endocannabinoid, 2-arachidonoylglycerol (2-AG); activities detailed in the next section|
|pancreatic lipase||PNLIP: 10q25.3; 13 exons||pancreas||465 amino acid precursor protein; hydrolyzes dietary triglycerides contained in bile acid micelles within the small intestine; requires colipase, which is secreted by the pancreas, for activity|
|pancreatic lipase related protein 2||PNLIPRP2: 10q25.3; 14 exons||pancreas||due to allelic variants there are coding and non-coding version of this gene; the coding version produces a 470 amino acid precursor protein; hydrolyzes dietary triglycerides, phospholipids, and galactolipids (from plants); human genome has two additional related genes PNLIPRP1 and PNLPRP3; protein encoded by PNLIPRP1 does not possess lipase activity|
Following absorption of the products of pancreatic lipase by the intestinal enterocytes, the re-synthesis of triglycerides occurs. The triglycerides are then solubilized in lipoprotein complexes (complexes of lipid and protein) called chylomicrons. A chylomicron contains lipid droplets surrounded by the more polar phospholipids and finally a layer of proteins. Triglycerides synthesized in the liver are packaged into VLDLs and released into the blood directly. Chylomicrons from the intestine are first released into the lymphatic system and then into the blood at the left subclavian vein for delivery of dietary fatty acids to the various tissues for storage (adipose tissue) or production of energy through oxidation (primarily skeletal muscle and cardiac muscle).
There are exceptions to the packaging of dietary lipids into chylomicrons within the intestinal enterocytes. The exceptions are short-chain (less than 6 carbon atoms) and medium-chain (6 to 12 carbons) fatty acids. Although the bulk of dietary fatty acids are long-chain (14 to 22 carbon atoms) fatty acids in triglycerides (abbreviated LCT) some triglycerides contain medium-chain fatty acids (abbreviated MCT). When MCT are hydrolyzed by pancreatic lipases the released fatty acids easily diffuse into the intestinal enterocytes and are passed directly to the portal circulation, bypassing the lymphatic system. Most, if not all, of the short-chain fatty acids (butyrate, propionate, and acetate) that are absorbed from the intestines are produced through the action of gut microbiota (bacteria) metabolism of soluble and insoluble fiber in the diet and these short-chain fatty acids also directly enter the blood from the intestinal enterocytes.
The triglyceride components of VLDLs and chylomicrons are hydrolyzed to free fatty acids and glycerol in the capillaries of tissues such as adipose tissue, heart, and skeletal muscle by the actions of lipoprotein lipase (LPL) and in the liver through the actions of hepatic triglyceride lipase [HTGL; encoded by the lipase C, hepatic (LIPC) gene]. The free fatty acids are then absorbed by the cells and the glycerol is returned, via the blood, to the liver (principal site) and kidneys. Within the liver the glycerol can then be converted to the glycolytic intermediate dihydroxyacetone phosphate (DHAP) and incorporated into the gluconeogenesis pathway or phosphorylated by glycerol kinase to glycerol-3-phosphate for reuse in triglyceride synthesis.
The classification of blood lipoprotein complexes is distinguished based upon the density of the different lipoproteins. As lipid is less dense than protein, the lower the density of lipoprotein the less protein there is in the particle.
Mobilization of Fat Stores
The primary sources of fatty acids for oxidation are dietary and mobilization from cellular stores. Fatty acids from the diet are absorbed from the gut, packaged into lipoprotein particles called chylomicrons within intestinal enterocytes and then delivered to cells of the body via transport in the blood. Fatty acids are stored in the form of triglycerides (triacylglycerides: TAGs or TGs) within all cell but predominantly within adipose tissue. In response to energy demands, the fatty acids of stored triglycerides can be mobilized for use by peripheral tissues. The release of metabolic energy, in the form of fatty acids, is controlled by a complex series of interrelated cascades that result in the activation of triglyceride hydrolysis. The primary intracellular lipases are adipose triglyceride lipase (ATGL, also called desnutrin), hormone-sensitive lipase (HSL), and lipase A (LIPA; also called lysosomal acid lipase, LAL). LIPA is the most important lipase involved in lysosomal lipid metabolism as evidenced by the fact that LIPA deficiency results in the significant accumulation of cholesteryl esters in tissues such as the spleen and liver. LIPA deficiency is commonly called Wolman disease or cholesterol ester storage disease.
Adipose triglyceride lipase: ATGL
ATGL/desnutrin belongs to the family of patatin domain-containing proteins that consists of nine human members. The patatin domain was originally discovered in lipid hydrolases of certain plants and named after the most abundant protein of the potato tuber, patatin. Because some members of the family act as phospholipases, the proteins were originally called patatin-like phospholipase domain-containing protein A1 to A9 (PNPLA1–PNPLA9). ATGL (designated PNPLA2 in the patatin domain nomenclature) preferentially hydrolyzes triglycerides. The human ATGL gene (official gene symbol: PNPLA2) is located on chromosome 11p15.5 and is composed of 8 exons encoding a 504 amino acids protein. In analogy with patatin, the active site of ATGL contains an unusual catalytic dyad (Ser47 and Asp166) within the patatin domain in the N-terminal half of the enzyme. The C-terminal half of the enzyme comprises the regulatory functions and also contains a predicted hydrophobic region involved in lipid droplet (LD) binding.
ATGL expression and enzyme activity are both under complex regulation. Expression of ATGL is induced by peroxisome proliferator-activated receptor (PPAR) agonists, glucocorticoids, and fasting. In addition, activation of FoxO1 by SIRT1-mediated deacetylation activates lipolysis by increasing ATGL expression. Conversely, silencing of SIRT1 has the opposite effect. Increased insulin release and food intake both result in decreased expression of ATGL. Reductions in ATGL expression have also been shown to be associated with mTOR complex 1 (mTORC1)-dependent signaling. The level of lipase activity of ATGL (as well as HSL) does not always correlate to the level of expression of the gene. For example, TNFα activity reduces both ATGL and HSL expression at the level of the gene but result in increased lipase activity resulting in fatty acid and glycerol release from triglycerides. Similarly, the use of non-selective beta blockers (e.g. isoproterenol) results in the same type of gene inhibition with enzyme activation. The discrepancy between ATGL and HSL mRNA levels and enzyme activities is the result of extensive post-translational regulation of both ATGL and HSL.
There are two known serine residues in ATGL that are subject to phosphorylation. Unlike phosphorylation of HSL (described below), ATGL phosphorylation is not PKA-dependent. In the mouse, it has been shown that AMPK phosphorylates ATGL resulting in increased lipase activity. However, it is important to point out that there remains a level of controversy as to the role of AMPK in the regulation of the activity of ATGL since induction, inhibition, and no effects results have been published.
In addition to phosphorylation regulating ATGL activity, the enzyme requires a coactivator protein for full lipase activity. This coactivator gene was originally identified as comparative gene identification-58, CGI-58. The term comparative gene identification relates to the use of computational methods to identify protein sequences highly conserved across various species and CGI-58 was originally discovered in a screen comparing the proteomes of humans and C. elegans. The official nomenclature for CGI-58 is α/β hydrolase domain-containing protein-5 (ABHD5; also identified as 1-acylglycerol-3-phosphate O-acyltransferase), owing to the presence of an α/β hydrolase domain commonly found in esterases, thioesterases, and lipases. It is unlikely that the ABHD5 protein possesses hydrolase activity because an asparagine residue is found in the catalytic domain where other hydrolases have a nucleophilic serine residue that is required for enzymatic activity. In addition to functioning as an ATGL coactivator, ABHD5 has also been shown to possess enzymatic activity as an acyl-CoA-dependent acylglycerol-3-phosphate acyltransferase (AGPAT). The physiological significance of this activity is currently unknown but it may be involved in the regulation of phosphatidic acid or lysophosphatidic acid signaling.
Additional proteins associated with lipid droplets (LD) in adipocytes participate in the ABHD5-mediated regulation of ATGL. In resting adipocytes of both WAT and BAT, the LD protein perilipin-1 interacts with ABHD5, preventing its binding to and, induction of ATGL. Following β-adrenergic stimulation of WAT, PKA phosphorylates perilipin-1 at multiple sites resulting in the release of ABHD5 which in turn, binds and stimulates ATGL. This demonstrates that β-adrenergic stimulation of PKA induces ATGL activity, not by direct phosphorylation of ATGL itself, but through phosphorylation of perilipin-1. This model of ATGL regulation is evident from frameshift mutants that have been identified in human perilipin-1. These mutations are identified as V398fs and L404fs indicating that the frame shift occurs at valine 398 and leucine 404, respectively. Each of these mutant ATGL proteins fails to bind ABHD5, resulting in unrestrained lipolysis, partial lipodystrophy, hypertriglyceridemia, and insulin resistance.
In non-adipose tissues with high rates of triglyceride hydrolysis, such as skeletal muscle and liver, regulation of ATGL activity occurs via a mechanism distinct from that in adipose tissues. In these tissues, perilipin-1 is replaced by perilipin-5. During fasting, perilipin-5 recruits both ATGL and ABHD5 to LD by direct binding of the enzyme and its coactivator. Data indicates that perilipin-5 is involved in the interaction of LD with mitochondria and thereby inhibits ATGL-mediated triglyceride hydrolysis. Other perilipins exist in cells including perilipin-2, -3, and -4 but it is unclear if these proteins are also involved in regulating the association of ATGL with LD. In hepatocyte cell lines it has been shown that overexpression of perilipin-2 inhibits ATGL activity by restricting its physical access to LD.
Recently, a specific peptide inhibitor for ATGL was isolated from white blood cells, specifically mononuclear cells. This peptide was originally identified as being involved in the regulation of the G0 to G1 transition of the cell cycle. This peptide was, therefore, called G0G1 switch protein 2 (encoded by the G0S2 gene). The protein is found in numerous tissues, with highest concentrations in adipose tissue and liver. In adipose tissue G0S2 expression is very low during fasting but increases after feeding. Conversely, fasting or PPARα-agonists increase hepatic G0S2 expression. The protein has been shown to localize to LDs, cytoplasm, ER, and mitochondria. These different subcellular localizations likely relate to multiple functions for G0S2 in regulating lipolysis, the cell cycle, and, possibly, apoptosis via its ability to interact with the mitochondrial antiapoptotic factor Bcl-2. With respect to ATGL regulation, the binding of the enzyme to LDs and subsequent is dependent on a physical interaction between the N-terminal region of G0S2 and the patatin domain of ATGL.
The delivery of ATGL to LD requires functional vesicular transport. When essential protein components of the transport machinery are defective or missing, such as ADP-ribosylation factor 1 (ARF1), small GTP-binding protein 1 (SAR1), the guanine-nucleotide exchange factor Golgi-Brefeldin A resistance factor (GBF1), or the coatamer protein coat-complex I (COPI) and COPII, ATGL translocation to LDs is blocked and the enzyme remains associated with the ER.
Hormone-sensitive lipase: HSL
A landmark study published in 1964 demonstrated that a lipolytic activity present in adipose tissue was induced by hormonal stimulation. This work described the isolation and characterization of both HSL and monoacylglyceride lipase (MGL). This original study demonstrated that HSL had a higher level of activity as a diglyceride hydrolase than as a triglyceride hydrolase. Nevertheless, it became dogma that HSL was rate-limiting for the catabolism of fat stores in adipose and many non-adipose tissues. However, when HSL-deficient mice were produced and shown to efficiently hydrolyze triglycerides the model began to emerge demonstrating ATGL, and not HSL, to be rate-limiting for adipose tissue triglyceride hydrolysis. HSL-deficient mice do not accumulate triglycerides in either adipose or non-adipose tissues, but they do accumulate large amounts of diglycerides in many tissues. This indicated for the first time that HSL was more important as a diglyceride hydrolase than a triglyceride hydrolase. It is now accepted that ATGL is responsible for the initial step of lipolysis in human adipocytes, and that HSL is rate-limiting for the catabolism of diglycerides. HSL not only hydrolyzes diglycerides but is also active at hydrolyzing ester bonds of many other lipids including triglycerides, monoglycerides, cholesteryl esters, retinyl esters, and short-chain carbonic acid esters.
The gene encoding HSL (official symbol: LIPE for lipase E, hormone sensitive) is located on chromosome 19q13.2 and is composed of 15 exons. Alternative exon usage results in tissue-specific differences in mRNA and protein size. In adipose tissue the HSL protein is composed of 775 amino acids, whereas the testicular form is composed of 1,076 amino acids. The larger HSL isoform found in testis is due to the inclusion of a novel exon located 16 kb upstream of the exons that encode the adipose tissue (and other tissues) form of HSL. The expression profile of HSL, within adipocytes, essentially mirrors that of ATGL. Highest mRNA and protein concentrations are found in WAT and BAT with low levels of expression found in muscle, testis, steroidogenic tissues, and pancreatic islets as well as several other tissues. Functional studies on the enzyme have identified an N-terminal lipid-binding region, the α/β hydrolase fold domain including the catalytic triad, and the regulatory module containing all known phosphorylation sites important for regulation of enzyme activity.
HSL and ATGL share many regulatory similarities yet the mechanisms of the regulatory processes differ markedly between the two enzymes. In adipose tissue, HSL enzyme activity is strongly induced by β-adrenergic stimulation, conversely insulin has a strong inhibitory effect. While β-adrenergic stimulation regulates ATGL primarily via recruitment of the coactivator ABHD5, HSL is a major target for PKA-mediated phosphorylation. Additional kinases, including AMPK, extracellular signal-regulated kinase (ERK), glycogen synthase kinase-4 (GSK-4), and Ca2+/calmodulin-dependent kinase 1 (CAMK1), also phosphorylate HSL to modulate the activity of the enzyme. HSL has at least five potential phosphorylation sites, of which S660 and S663 appear to be particularly important for hydrolytic activity.
Phosphorylation of HSL affects enzyme activity only moderately resulting in an approximate 2-fold increase in hydrolytic activity. For full activation, HSL must gain access to LD, which, in adipose tissue, is mediated by perilipin-1. In addition to phosphorylating HSL, PKA also phosphorylates perilipin-1 on six consensus serine residues. The result of these phosphorylations is the binding of HSL to the N-terminal region of perilipin-1. This protein-protein interaction is the means by which HSL gains access to LD. The net effect, of HSL-phosphorylation and enzyme translocation to LD, coupled with ATGL activation by ABHD5, leads to a more than 100-fold increase in triglyceride hydrolysis in adipocytes.
Additional factors modulate the activation of HSL and ATGL. One such factor is nuclear receptor-interacting protein 140 (RIP140; encoded by the NRIP1 gene) which induces lipolysis by binding to perilipin-1, increasing HSL translocation to LD, and activating ATGL via ABHD5 dissociation from perilipin-1. In non-adipose tissues, such as skeletal muscle, HSL is activated by phosphorylation in response to epinephrine (β-adrenergic receptor-mediated activation of PKA) and muscle contraction (calcium release from sarcoplasmic reticulum). Since skeletal muscles lack perilipin-1 it has not yet been determined which alternative mechanisms regulate HSL access to LD.
Insulin-mediated deactivation of lipolysis is associated with transcriptional downregulation of ATGL and HSL expression. Additionally, insulin signaling results in phosphorylation and activation of various phosphodiesterase (PDE) isoforms (predominantly PDE3B) by PKB/AKT leading to PDE-catalyzed hydrolysis of cAMP which in turn results in reduced activation of PKA. These actions turn off lipolysis by preventing phosphorylation of both HSL and perilipin-1, activation and translocation of HSL, and activation of ATGL by ABHD5. In addition to its peripheral action, insulin also functions within the sympathetic nervous system to inhibit lipolysis in WAT. Increased insulin levels in the brain inhibit HSL and perilipin phosphorylation which results in reduced HSL and ATGL activities.
Monoglyceride lipase: MGL
MGL is considered to be the rate-limiting enzyme for the breakdown of monoglycerides that are the result of both extracellular and intracellular lipolysis pathways. The extracellular generation of monoglycerides is the result of the action of endothelial cell lipoprotein lipase (LPL) on lipoprotein particle-associated triglycerides. Intracellular hydrolysis of triglycerides by ATGL and HSL, as well as intracellular phospholipid hydrolysis by phospholipase C (PLC) and membrane-associated diglyceride lipase α and β results in the generation of MGL substrates.
The MGL gene (official gene symbol: MGLL) is located on chromosome 3q21.3 and is composed of 13 exons that generate at least three isoforms via alternative splicing. MGL isoform 1 is composed of 313 amino acids, isoform 2 is composed of 303 amino acids, and isoform 3 is composed of 283 amino acids. MGL has been shown to localize to lipid droplets (LD), cell membranes, and the cytosol. The enzyme is ubiquitously expressed with highest levels of expression in adipose tissue. MGL shares homology with esterases, lysophospholipases, and haloperoxidases. The enzyme contains a consensus GXSXG motif within a catalytic triad that is typical of lipases and esterases.
MGL is critically important for efficient degradation of monoglycerides since it has been shown in mouse models that lack of MGL impairs lipolysis and is associated with increased MG levels in adipose and non-adipose tissues alike. MGL has received particular attention in recent years due to the discovery that the enzyme is responsible for the inactivation of 2-arachidonoylglycerol (2-AG) which is an endogenous cannabinoid monoglyceride (endocannabinoid).
For more information on the activities of ATGL, HSL and other lipases regulating triglyceride levels in adipocytes visit the Adipose Tissue page.
In contrast to the hormonal activation of adenylate cyclase and (subsequently) hormone-sensitive lipase in adipocytes, the mobilization of fat from adipose tissue is inhibited by numerous stimuli. The most significant inhibition is that exerted upon adenylate cyclase by insulin. When an individual is in the well fed state, insulin released from the pancreas prevents the inappropriate mobilization of stored fat. Instead, any excess fat and carbohydrate are incorporated into the triglyceride pool within adipose tissue.
Cellular Uptake of Fatty Acids
When fatty acids are released from adipose tissue stores they enter the circulation as free fatty acids (FFAs) and are bound to albumin for transport to peripheral tissues. When the fatty acid–albumin complexes interact with cell surfaces the dissociation of the fatty acid from albumin represents the first step of the cellular uptake process. Uptake of fatty acids by cells involves membrane proteins with high affinity for fatty acids. There are several members of the fatty acid receptor family including fatty acid translocase (FAT/CD36), plasma membrane-associated fatty acid-binding protein (FABPpm), and fatty acid transport proteins (FATPs). The FATPs are a family of at least six fatty acid transport proteins (FATP1–FATP6) that are also members of the solute carrier family of transporters. The FATPs facilitate the uptake of very long-chain (VLCFA) and long-chain fatty acids (LCFA).
Table of Mammalian Fatty Acid Transporters
|FAT/CD36||fatty acid translocase; FAT is also known as CD36 which is a member of the scavenger receptor class (class B scavenger receptors) of receptors that bind lipids and lipoproteins of the LDL family; the CD36 gene is located on chromosome 7q21.11 and composed of 18 exons that generate 15 alternatively spliced mRNAs that encode six distinct isoforms of the protein|
|FABPpm||plasma membrane-associated fatty acid-binding protein; originally characterized as a plasma membrane-associated fatty acid transporter this protein was later demonstrated to be the mitochondrial isoform of glutamate-oxalate transaminase (gene symbol: GOT2); gene located on chromosome 16q21 and is composed of 10 exons that generate two alternatively spliced mRNAs encoding precursor proteins of 430 amino acids (isoform 1) and 387 amino acids (isoform 2)|
|FATP1||FATP1 is SLC27A1; FATP1 is also known as acyl-CoA synthetase very long-chain family, member 5 (ACSVL5); highest levels of expression in adipose tissue, skeletal and heart muscle; the SLC27A1 gene is located on chromosome 19p13.11 and is composed of 16 exons encoding a 646 amino acid protein|
|FATP2||FATP2 is SLC27A2; FATP2 is also known as acyl-CoA synthetase very long-chain family, member 1 (ACSVL1) as well as very long-chain acyl-CoA synthetase (VLCS); highest levels of expression in liver and kidney; present in peroxisome and microsomal membranes; the SLC27A2 gene is located on chromosome 15q21.2 composed of 10 exons that generate two alternatively spliced mRNAs that encode precursor proteins of 620 amino acids (isoform 1) and 567 amino acids (isoform 2)|
|FATP3||FATP3 is SLC27A3; FATP3 is also known as acyl-CoA synthetase very long-chain family, member 3 (ACSVL3); the SLC27A3 gene is located on chromosome 1q21.3 and is composed of 10 exons that generate two alternatively spliced mRNAs that encode precursor proteins of 683 amino acids (isoform 1) and 648 amino acids (isoform 2)|
|FATP4||FATP4 is SLC27A4; FATP4 is also known as acyl-CoA synthetase very long-chain family, member 4 (ACSVL4); is the major intestinal long-chain fatty acid transporter; the SLC27A4 gene is located on chromosome 9q34.11 and is composed of 14 exons that encode a 643 amino acid protein|
|FATP5||FATP5 is SLC27A5; FATP5 is also known as acyl-CoA synthetase very long-chain family, member 6 (ACSVL6), also as very long-chain acyl-CoA synthetase-related protein (VLACSR), also as very long-chain acyl-CoA synthetase homolog 2 (VLCSH2), and also as bile acid-CoA synthetase; ER-associated enzyme; highest levels of expression in the liver; capable of activating 24- and 26-carbon VLCFAs; also catalyzes the first reaction in the conjugation of bile acids with glycine and taurine (this activity is identified as bile acid-CoA synthetase: BACS); the SLC27A5 gene is located on chromosome 19q13.43 and is composed of 11 exons that generate two alternatively spliced mRNAs encoding proteins of 690 amino acids (isoform 1) and 606 amino acids (isoform 2)|
|FATP6||FATP6 is SLC27A6; FATP6 is also known as acyl-CoA synthetase very long-chain family, member 2 (ACSVL2), very long-chain acyl-CoA synthetase homolog 1 (VLCSH1); expressed at highest levels in the heart; protein only detected in heart and testis; exhibits a preference for the transport of palmitic acid and linoleic acid, does not transport fatty acids less than 10 carbons long; the SLC27A6 gene is located on chromosome 5q23.3 and is composed of 112 exons that generate three alternatively spliced mRNAs all of which encode the same 619 amino acid protein|
The result of the interaction of fatty acids with plasma membrane receptors/binding proteins is a transmembrane concentration gradient. At the plasma membrane the apparent pKa of the fatty acid shifts from about 4.5 in aqueous solutions to about 7.6. This pKa change is independent of fatty acid type. As a consequence, about half of the fatty acids are present in the un-ionized form. This local environment effect promotes a transfer (flip-flop) of uncharged fatty acids from the outer leaflet across the phospholipid bilayer. At the cytosolic surface of the plasma membrane, fatty acids can associate with the cytosolic fatty acid binding protein (FABPc) or with caveolin-1. Caveolin-1 is a constituent of caveolae (Latin for little caves) which are specialized “lipid rafts” present in flask-shaped indentations in the plasma membranes of many cells types that perform a number of signaling functions by serving as lipid delivery vehicles for subcellular organelles. In order that the fatty acids that are thus taken up to be directed to the various metabolic pathways (e.g. oxidation or triglyceride synthesis) they must be activated to acyl-CoA.
Members of the fatty acid transport protein (FATP) family have been shown to possess acyl-CoA synthetase (ACS) activity. Activation of fatty acids by FATPs occurs at the highly conserved cytosolic AMP-binding site of these proteins. The overall process of cellular fatty acid uptake and subsequent intracellular utilization represents a continuum of dissociation from albumin by interaction with the membrane-associated transport proteins, binding to FABPc and caveolin-1 at the cytosolic plasma membrane, activation to acyl-CoA (in many cases via FATP action) followed by intracellular trafficking via FABPc and/or caveolae to sites of metabolic disposition.
Roles of Intracellular Fatty Acid Binding Proteins, FABP
Fatty acid binding proteins (FABPs) represent a family of intracellular lipid-binding proteins whose functions are to reversibly bind intracellular hydrophobic ligands and transport the bound ligand throughout the various cellular compartments, including the peroxisomes, mitochondria, endoplasmic reticulum, and nucleus. FABPs have broad binding characteristics which includes the ability to bind long-chain (C16–C20) fatty acids (LCFAs), eicosanoids, bile salts, and peroxisome proliferators. There are currently nine well characterized FABP genes in the human genome, four of which are located in the same region of the q arm of chromosome 8 (FABP4, FABP5, FABP8, and FABP9). Each of these FABPs was originally named for the tissue in which it was first isolated and characterized or in which it predominates. However, many of these FABPs are expressed in numerous tissues.
Expression of a particular FABP gene directly reflects the lipid metabolic capacity of that tissue. In high lipid metabolizing tissues, such as the liver, adipose tissue, and the heart, the expressed FABPs can account for 1%–5% per cent of total soluble cytosolic proteins. The expression of FABPs in the cell is essential for the binding of hydrophobic ligands, particularly free fatty acids, in order to reduce the detergent-like properties of high concentrations of fatty acids, thereby keeping them soluble. FABPs are critical to the process of lipid trafficking within cells to the various cellular compartments where they will be stored, oxidized, utilized for membrane synthesis, and for their roles in the activation of nuclear receptors. With respect to the latter function, it has been shown that FABPs are involved in the targeting of fatty acids to transcription factors of the peroxisome proliferator-activated receptor (PPAR) family. In addition to their importance in intracellular lipid trafficking, many FABPs interact with phospholipid-rich membranes and bind eicosanoid intermediates protecting these substrates against peroxidation strongly implicating these proteins in antioxidant-type behavior.
Table of Fatty Acid Binding Proteins
|FABP||Alternate Names||Tissue Location||Functions / Comments|
|Z protein, hepatic FABP, heme-binding protein||liver, intestine, pancreas, kidney, lung, stomach||represents up to 5% of hepatocyte cytosolic protein; unique ability to bind multiple ligands at once; in addition to various free fatty acids FABP1 binds binds fatty acyl-carnitines, intermediates in glyceride synthesis, lysophospholipids, cholesterol, bile acids, prostaglandins, lipoxygenase products, retinoids, heme and bilirubin; FABP1 also binds numerous xenobiotic drugs such as NSAIDs, fibrates, beta blockers, and benzodiazepines; the FABP1 gene is located on chromosome 2p11.2 and is composed of 4 exons encoding a 127 amino acid protein|
|gut FABP, gFABP||intestine, liver||mediates dietary fat absorption of free long-chain fatty acids (LCFAs); the FABP2 gene is located on chromosome 4q26 and is composed of 4 exons encoding a 132 amino acid protein; a polymorphism in codon 54 that causes a substitution of alanine for threonine (A54T) is associated with increased serum triglyceride accumulation, weight gain, and insulin resistance|
|O-FABP, mammary-derived growth inhibitor, MDGI||skeletal and heart muscle, brain, kidney, lung, stomach, testes, placenta, ovary, brown adipose tissue (BAT), adrenal glands, mammary glands||makes up 4%–8% of cytosolic protein in the heart; major function is to traffic fatty acids to the mitochondria for oxidation; also binds non-prostanoid oxygenated fatty acids; measurement of protein in the blood is considered an early marker for myocardial infarct; may also be a marker for Creutzfeldt–Jakob disease (CJD) by measurement of levels in the cerebrospinal fluid; the FABP3 gene is located on chromosome 1p35.2 and is composed of 5 exons that generate two alternatively spliced mRNAs encoding proteins of 144 amino acids (isoform 1) and 133 amino acids (isoform 2)|
|adipocyte protein 2, aP2||adipocytes and macrophages of adipose tissue, dendritic cells||specific binding capacity for LCFAs; is a marker for adipocyte maturation; modulates the activity of HSL through direct interaction; macrophage FABP4 modulates inflammatory responses; recently demonstrated to be a secreted adipokine involved in regulating hepatic glucose production; the FABP4 gene is located on chromosome 8q21.13 and composed of 4 exons that encode a 132 amino acid protein|
|psoriasis-associated FABP (PA-FABP); keratinocyte-type FABP (KFABP)||skin, brain, stomach, intestines, kidney, liver, lung, heart, skeletal muscle, tongue, adipocytes, macrophages, dendritic cells, testes, retina, placenta, spleen||physiological ligands not completely determined; in vitro the protein binds stearic acid with high affinity while having reduced affinity for unsaturated fatty acids; interacts with HSL like FABP3; the FABP5 gene is located on chromosome 8q21.13 and is composed of 4 exons that encode a 135 amino acid protein|
|ileal lipid-binding protein (ILBP); gastrotropin; intestinal bile acid-binding protein (I-BABP)||ileum, stomach, adrenal glands, ovary||involved in enterohepatic circulation of bile acids; binds bile acids with highest affinity then fatty acids; interacts with the ileal bile acid transporter protein; the FABP6 gene is located on chromosome 5q33.3 and is composed of 7 exons that generate three alternatively spliced mRNAs that encode proteins of 177 amino acids (isoform 1) and 128 amino acids (isoform 2)|
|brain lipid-binding protein (BLBP)||brain, glial cells, mammary glands, retina||grey matter neurons do not express FABP7; highest affinity for long-chain omega-3 polyunsaturated fatty acids (PUFAs) particularly EPA and DHA; also binds oleic acid and arachidonic acid but does not bind palmitic acid or retinoic acid; the FABP7 gene is located on chromosome 6q22.31 and is composed of 5 exons that generate four alternatively spliced mRNAs, each of which encode a distinct protein isoform|
|peripheral myelin protein 2 (PMP2); myelin P2 protein||Schwann cells, peripheral nervous system||binds LCFAs; thought to be involved in stabilizing myelin membranes; official gene symbol is PMP2; the PMP2 gene is located on chromosome 8q21.13 and is composed of 4 exons that generate two alternatively spliced mRNAs encoding proteins of 132 amino acids (isoform 1) and 60 amino acids (isoform 2)|
|testes lipid-binding protein (TLBP);||testes, mammary glands, salivary glands||precise functions not clearly defined; thought to be involved in protection of fatty acids in sperm from oxidation; the FABP9 gene is located on chromosome 8q21.13 and is composed of 4 exons that encode a 132 amino acid protein|
Mitochondrial (beta) β-Oxidation Reactions
Fatty Acid Activation
Oxidation of fatty acids occurs in the mitochondria and the peroxisomes (see below). Fatty acids of between 4–8 and between 6–16 carbon atoms in length, referred to as short- and medium-chain fatty acids (SCFAs and MCFAs, respectively), are oxidized exclusively in the mitochondria. Long-chain fatty acids (LCFAs: 10–18 carbons long) are oxidized in both the mitochondria and the peroxisomes with the peroxisomes exhibiting preference for 14-carbon and longer LCFAs. Very-long-chain fatty acids (VLCFAs: C18–C26; often designated as any fatty acid of 22 carbons and longer) are preferentially oxidized in the peroxisomes. However, given that peroxisomes are unable to completely oxidize fatty acids, the chain shortened free fatty acids, or their carnitine esters, are released and taken up by the mitochondria for complete oxidation to CO2 and H2O.
Long-chain fatty acids must be activated in the cytoplasm before being oxidized in the mitochondria. Medium-chain and short-chain fatty acids are activated within the matrix of the mitochondria. Fatty acid activation is catalyzed by fatty acyl-CoA synthetases (also called acyl-CoA ligases or thiokinases). The net result of this activation process is the consumption of two molar equivalents of ATP. Humans express at least 26 acyl-CoA synthetases with several of these enzymes also being involved in fatty acid transport into cells (FATP1–FATP6) as indicated in the Table above in the Cellular Uptake of Fatty Acids section. The various acyl-CoA synthetases exhibit different substrate specificities, subcellular localization, and tissue distribution. Additional members of the family are the long-chain acyl-CoA synthetases, the medium-chain acyl-CoA synthetases, the short-chain acyl-CoA synthetases, and the bubblegum family acyl-CoA synthetases.
Fatty acid + ATP + CoA → Acyl-CoA + PPi + AMP
Table of the Mammalian Acyl-CoA Synthetase Family
|Gene Symbol||Aliases||Location||Enzyme name / Comments|
|AACS||12q24.31||acetoacetyl-CoA synthetase; gene composed of 19 exons that encode a 672 amino acid protein|
|AASDH||4q12||aminoadipate-semialdehyde dehydrogenase; also called acyl-CoA synthetase family member 4, isoform 2; gene composed of 17 exons that encode a protein of 992 amino acids|
|ACSBG1||15q25.1||acyl-CoA synthetase bubblegum family member 1; gene composed of 19 exons that generate two alternatively spliced mRNAs; involved in brain VLCFA metabolism and myelogenesis|
|ACSBG2||19p13.3||acyl-CoA synthetase bubblegum family member 2; gene composed of 16 exons that generate five alternatively spliced mRNAs encoding three distinct isoforms; expression restricted to the testis|
|ACSF2||17q21.33||acyl-CoA synthetase family member 2; gene composed of 19 exons that generate six alternatively spliced mRNAs encoding five distinct isoforms|
|ACSF3||16q24.3||acyl-CoA synthetase family member 3; mitochondrial protein, high affinity for methylmalonate and malonate; gene composed of 17 exons that generate four alternatively spliced mRNAs encoding two distinct isoforms|
|ACSS1||20p11.21||acyl-CoA synthetase short-chain family member 1; mitochondrial protein primarily responsible for generation of mitochondrial acetyl-CoA from acetate; gene composed of 15 exons that generate four alternatively spliced mRNAs that encode four distinct isoforms|
|ACSS2||20q11.22||acyl-CoA synthetase short-chain family member 2; cytosolic protein primarily responsible for generation of acetyl-CoA from acetate; gene expression controlled by SREBP; gene composed of 22 exons that generate three alternatively spliced mRNAs encoding three distinct isoforms|
|ACSS3||12q21.31||acyl-CoA synthetase short-chain family member 3; gene composed of 19 exons that encode a 686 amino acid precursor protein|
|ACSM1||16p12.3||acyl-CoA synthetase medium-chain family member 1; mitochondrial protein; gene composed of 18 exons that encode a 577 amino acid protein|
|ACSM2A||16p12.3||acyl-CoA synthetase medium-chain family member 2A; mitochondrial protein; gene composed of 15 exons that generate three alternatively spliced mRNAs encoding two distinct isoforms|
|ACSM2B||16p12.3||acyl-CoA synthetase medium-chain family member 2B; mitochondrial protein; gene composed of 16 exons that generate two alternatively spliced mRNAs encoding the same protein|
|ACSM3||16p13.11||acyl-CoA synthetase medium-chain family member 3; mitochondrial protein; gene composed of 15 exons that generate two alternatively spliced mRNAs that encode two distinct isoforms|
|ACSM4||12p13.31||acyl-CoA synthetase medium-chain family member 4; mitochondrial protein; gene composed of 13 exons that encode a 580 amino acid precursor protein|
|ACSM5||16p12.3||acyl-CoA synthetase medium-chain family member 5; mitochondrial protein; gene composed of 14 exons that encode a 579 amino acid precursor protein|
|ACSL1||4q35.1||acyl-CoA synthetase long-chain family member 1; gene composed of 28 exons that generate five alternatively spliced mRNAs encoding four distinct isoforms|
|ACSL3||2q36.1||acyl-CoA synthetase long-chain family member 3; gene composed of 17 exons that generate two alternatively spliced mRNAs encoding the same protein|
|ACSL4||Xq23||acyl-CoA synthetase long-chain family member 4; gene composed of 17 exons that generate two alternatively spliced mRNAs encoding two distinct isoforms; preferentially recognizes arachidonic acid as substrate|
|ACSL5||10q25.2||acyl-CoA synthetase long-chain family member 5; gene composed of 23 exons that generate three alternatively spliced mRNAs encoding two distinct isoforms|
|ACSL6||5q31||acyl-CoA synthetase long-chain family member 6; gene composed of 23 exons that generate six alternatively spliced mRNAs encoding six distinct isoforms|
|SLC27A1||FATP1, ACSVL5||19p13.11||solute carrier family 27 (fatty acid transporter), member 1; also known as fatty acid transport protein 1 and acyl-CoA synthetase very long-chain family, member 5; see details above|
|SLC27A2||FATP2, ACSVL1||15q21.2||solute carrier family 27 (fatty acid transporter), member 2; also known as fatty acid transport protein 2 and acyl-CoA synthetase very long-chain family, member 1; see details above|
|SLC27A3||FATP3, ACSVL3||1q21.3||solute carrier family 27 (fatty acid transporter), member 3; also known as fatty acid transport protein 3 and acyl-CoA synthetase very long-chain family, member 3; see details above|
|SLC27A4||FATP4, ACSVL4||9q34.11||solute carrier family 27 (fatty acid transporter), member 4; also known as fatty acid transport protein 4 and acyl-CoA synthetase very long-chain family, member 4; see details above|
|SLC27A5||FATP5, ACSVL6||19q13.43||solute carrier family 27 (fatty acid transporter), member 5; also known as fatty acid transport protein 5 and acyl-CoA synthetase very long-chain family, member 6; see details above|
|SLC27A6||FATP6, ACSVL2||5q23.3||solute carrier family 27 (fatty acid transporter), member 6; also known as fatty acid transport protein 6 and acyl-CoA synthetase very long-chain family, member 2; see details above|
Fatty Acid Transport into Mitochondria
Short-chain and medium-chain fatty acids require no specific transport mechanism to enter the mitochondria for oxidation and, as indicated earlier, are activated by CoA attachment within the mitochondrial matrix. Also, because dietary short-chain and medium-chain fatty acids directly enter the portal circulation (they are not packaged into chylomicrons) they are rapidly oxidized within the liver. Long-chain fatty acids, present in the triglycerides of chylomicrons, or VLDL, or as free fatty acids released from adipose tissue require a specific mitochondrial transport mechanism to be oxidized. The transport of long-chain fatty acyl-CoAs into the mitochondria is accomplished via an acyl-carnitine intermediate, which itself is generated by the action of carnitine palmitoyltransferase 1 (CPT-1 or CPT-I) an enzyme that resides in the outer mitochondrial membrane.
There are three CPT-1 genes in humans identified as CPT1A, CPT1B, and CPT1C. Expression of CPT1A predominates in the liver and is thus, referred to as the liver isoform. CPT1B expression predominates in skeletal muscle and is thus, referred to as the muscle isoform. CPT1C expression is exclusive to the brain and testes. The CPT1A gene is located on chromosome 11q13.2 and consists of 21 exons that generate two alternatively spliced mRNAs encoding isoform 1 (773 amino acids) and isoform 2 (756 amino acids). The CPT1B gene is located on chromosome 22q13.33 and consists of 21 exons that generate several alternatively spliced mRNAs, all of which yield three distinct isoforms of the enzyme. The CPT1C gene is located on chromosome 19q13.3 and consists of 25 exons that generate several alternatively spliced mRNAs, all of which yield two distinct isoforms of the enzyme (isoform 1 is 792 amino acids; isoform 2 is 803 amino acids).
The activity of CPT1C is distinct from those of CPT1A and CPT1B in that it does not act on the same types of fatty acyl-CoAs that are substrates for the latter two enzymes, nor does it participate in the mobilization of fatty acids into the mitochondria. CPT1C does exhibit high-affinity for malonyl-CoA binding. Within the hypothalamus, brain CPT1C serves as a sensor of nutrient availability by binding malonyl-CoA which triggers a reduction in the release of the appetite promoting neuropeptides, neuropeptide Y (NPY) and Agouti-related peptide (AgRP) and an increase the release of the appetite suppressing neuropeptides, α-melanocyte stimulating hormone (α-MSH) and cocaine and amphetamine regulated transcript (CART). The net effect of increased hypothalamic malonyl-CoA binding to CPT1C is, therefore, satiety and appetite suppression.
Once a fatty acylcarnitine is generated at the outer mitochondrial membrane it is transported into the mitochondria through the action of carnitine acylcarnitine translocase, CACT. The CACT transporter is a member of the SLC family of transporters and as such is encoded by the SLC25A20 gene. The carnitine acylcarnitine translocase is located in the inner mitochondrial membrane where it facilitates acylcarnitine transport across the outer and inner mitochondrial membranes in exchange for free carnitine. Following CACT-mediated transfer of the CPT1-generated fatty acylcarnitines across the inner mitochondrial membrane, the fatty acyl-carnitine molecules are acted on by the inner mitochondrial membrane-associated carnitine palmitoyltransferase 2 (CPT-2 or CPT-II) regenerating the fatty acyl-CoA molecules. The CPT2 gene is located on chromosome 1p32.3 and consists of 5 exons that generate two alternatively spliced mRNAs. These mRNAs encode precursor proteins of 658 amino acids (isoform 1) and 635 amino acids (isoform 2).
In addition to the genes of the CPT family of carnitine acyltransferases, humans express two additional carnitine acyltransferases. The two additional enzymes are carnitine O-acetyltransferase encoded by the CRAT gene and carnitine octanoyltransferase encoded by the CROT gene. The CRAT gene is located on chromosome 9q34.11 and is composed of 18 exons that generate seven alternatively spliced mRNAs that collectively encode six distinct protein isoforms. The CROT gene is located on chromosome 7q21.12 and is composed of 21 exons that generate three alternatively spliced mRNAs that encode three distinct protein isoforms. The different CRAT mRNAs encode enzymes that are found in the mitochondrial matrix, the peroxisomes, and the nucleus. The substrate specificity of CRAT is for short-chain acyl-CoA esters. The CROT encoded enzyme is found in the peroxisomes where it has substrate preference for medium-chain acyl-CoAs. The major substrate for the CROT enzyme is 4,8-dimethylnonanoyl-CoA. The function of the CROT enzyme is to participate in the transport of medium- and long-chain fatty acyl-CoA molecules out of the peroxisomes to the cytosol and the mitochondria.
Processes of Mitochondrial Fatty Acid β-Oxidation
The process of mitochondrial fatty acid oxidation is termed β-oxidation since it occurs through the sequential removal of 2-carbon units by oxidation at the β-carbon position of the fatty acyl-CoA molecule. The oxidation of fatty acids and lipids in the peroxisomes (see below) also occurs via a process of β-oxidation but the enzymes are distinct from those used within the mitochondria. Each round of mitochondrial fatty acid β-oxidation involves four steps that, in order, are oxidation, hydration, oxidation, and cleavage. The first oxidation step in mitochondrial β-oxidation involves a family of FAD-dependent acyl-CoA dehydrogenases that act on saturated fatty acids. Each of these dehydrogenases has a range of substrate specificities determined by the length of the fatty acid.
Short-Chain Acyl-CoA dehydrogenase: SCAD
Short-chain acyl-CoA dehydrogenase (SCAD, also called butyryl-CoA dehydrogenase) prefers fats of 4–6 carbons in length. The SCAD enzyme (also known as ACAD3) is encoded by the ACADS (acyl-CoA dehydrogenase, short chain) gene which is located on chromosome 12q24.31 and is composed of 11 exons that generate two alternatively spliced mRNAs encoding proteins of 412 amino acids and 408 amino acids.
Medium-Chain Acyl-CoA Dehydrogeanse: MCAD
Medium-chain acyl-CoA dehydrogenase (MCAD; also known as ACAD1) prefers fats of 4–16 carbons in length with maximal activity for C10 acyl-CoAs. The MCAD enzyme is encoded by the ACADM gene which is located on chromosome 1p31.1 and is composed of 13 exons generate five alternatively spliced mRNAs each encoding a unique protein isoform.
Long-Chain Acyl-CoA Dehydrogenase
Long-chain acyl-CoA dehydrogenase (LCAD; also known as ACAD4) prefers fats of 10-18 carbons in length with maximal activity for C12 acyl-CoAs. The LCAD enzyme is encoded by the ACADL gene which is located on chromosome 2q34 and is composed of 12 exons that encode a 430 amino acid precursor protein. However, due to low level expression of the ACADL gene in humans, the encoded acyl-CoA dehydrogenase plays a limited, if at all, role in mitochondrial fatty acid oxidation. Expression of the ACADL gene is seen in alveolar type II pneumocytes which are the specialized cells of the alveolar epithelium that synthesize and secrete pulmonary surfactant. Pulmonary surfactant is a complex of lipid (90%) and protein (10%) where the primary lipid is dipalmitoylphosphatidylcholine (DPPC; also called dipalmitoyllecithin).
Very Long-Chain Acyl-CoA Dehydrogenase
Very long-chain acyl-CoA dehydrogenase (VLCAD; also known as ACAD6) prefers fats of 16-24 carbons and is inactive on any fatty acid less than 12 carbons. The VLCAD enzyme is encoded by the ACADVL gene which is located on chromosome 17p13.1 and is composed of 22 exons that generate four alternatively spliced mRNAs each of which encode distinct protein isoforms. The isoform 4 encoding ACADVL mRNA does not initiate translation efficiently and is, therefore, a likely mRNA candidate for nonsense mediated decay, NMD. Unlike the localization of SCAD and MCAD to the mitochondrial matrix, VLCAD is an inner mitochondrial membrane-localized enzyme.
Additional Acyl-CoA Dehydrogenase Family Members
In addition to the fatty acyl-CoA dehydrogenases, SCAD, MCAD, LCAD, and VLCAD, humans express seven additional acyl-CoA dehydrogenases, not all of which are involved in lipid oxidation. These additional enzymes are isovaleryl-CoA dehydrogenase (also known as ACAD2; encoded by the IVD gene), glutaryl-CoA dehydrogenase (also known as ACAD5; encoded by the GCDH gene), short/branched-chain acyl-CoA dehydrogenase (also known as ACAD7; encoded by the ACADSB gene), ACAD8, ACAD9, ACAD10, and ACAD11.
The IVD and ACAD8 encoded proteins are involved in the catabolism of leucine and valine, respectively. The GCDH encoded enzyme is involved in the conversion of glutaryl-CoA to crotonyl-CoA derived through the catabolism of tryptophan and the catabolism of lysine. The ACADSB encoded enzyme prefers the branched chain acyl-CoA, 2-methylbutryl-CoA, which is a product of the catabolism of isoleucine, but is also functional on the short straight-chain acyl-CoAs, butyryl-CoA and hexanoyl-CoA. Although ACAD9 has dehydrogenase activity towards palmitoyl-CoA and stearoyl-CoA in vitro, the enzyme appears to be involved in the assembly of complex I of mitochondrial oxidative phosphorylation. The ACAD10 encoded enzyme is functional only on the CoA derivative of 2-methyl substituted pentadecanoic (C15:0) acid. The ACAD11 encoded enzyme appears to be specific for the CoA derivative of behenic (C22:0) acid.
Similarities and Differences in Oxidation of Different Length Fatty Acids
Although the oxidation of long-chain saturated fatty acids occurs with a chemistry that is the same as that for the oxidation of medium-chain and short-chain saturated fatty acids, there are different sets of enzymes involved. Following the FAD-dependent acyl-CoA dehydrogenase step, the next three steps in mitochondrial β-oxidation involve a hydration step, another oxidation step, and finally a hydrolytic reaction that requires CoA and releases acetyl-CoA and a fatty acyl-CoA two carbon atoms shorter than the initial substrate.
The enzymes of long-chain fatty acid oxidation are localized to the inner mitochondrial membrane. In the oxidation of these substrates, until they become medium-chain length, the water addition is catalyzed by an enoyl-CoA hydratase activity, the second oxidation step is catalyzed by an NAD-dependent long-chain hydroxacyl-CoA dehydrogenase activity (3-hydroxyacyl-CoA dehydrogenase activity), and finally the cleavage into an acyl-CoA and an acetyl-CoA is catalyzed by a thiolase activity. For the oxidation of long-chain saturated fatty acids these three activities are encoded in a multifunctional enzyme called the mitochondrial trifunctional protein, MTP (also known simply as trifunctional protein: TFP). MTP is composed of eight protein subunits, four α-subunits encoded by the HADHA gene and four β-subunits encoded by the HADHB gene. The α-subunits contain the enoyl-CoA hydratase and long-chain hydroxyacyl-CoA dehydrogenase activities, while the β-subunits possess the 3-ketoacyl-CoA thiolase (β-ketothiolase or just thiolase) activity.
Medium-chain and short-chain saturated fatty acids are oxidized by soluble mitochondrial matrix enzymes. Following the action of MCAD and SCAD the resulting enoyl-CoAs are substrates for the enoyl-CoA hydratase encoded by the ECHS1 (enoyl-CoA hydratase, short chain 1) gene. The ECHS1 encoded enzyme is often referred to as crotonase. The next oxidation step is catalyzed by hydroxyacyl-CoA dehydrogenase which is encoded by the HADH gene. This dehydrogenase exhibits highest specificity for medium-chain saturated fatty acids. Mutations in the HADH gene are associated with familial hyperinsulinemic hypoglycemia. The thiolase reaction is catalyzed by the ACAA2 encoded enzyme (see the Table below) which is also referred to as medium-chain 3-ketoacyl-CoA thiolase, MCKAT. The mammalian genome actually encodes five distinct enzymes with thiolase activity as outlined in the following Table.
Table of Mammalian Thiolase Genes
|Thiolase Gene Symbol||Comments|
|ACAA1||acetyl-CoA acyltransferase 1; also called peroxisomal 3-oxoacyl-CoA thiolase; involved in peroxisomal fatty acid β-oxidation; located on chromosome 3p22.2 spanning 11 kb composed of 12 exons that generate two alternatively spliced mRNAs encoding two isoforms of the enzyme (isoform a is 424 amino acids, isoform b is 331 amino acids)|
|ACAA2||acetyl-CoA acyltransferase 2; also called mitochondrial 3-oxoacyl-CoA thiolase or medium-chain 3-ketoacyl-CoA thiolase (MCKAT); catalyzes the terminal reaction of mitochondrial fatty acid β-oxidation of medium- and short-chain fatty acids and the breakdown of the ketone, acetoacetyl-CoA, to two moles of acetyl-CoA; activity similar to that catalyzed by HADHB of the MTP; located on chromosome 18q21.1 and composed of 10 exons that encode a 397 amino acid protein|
|ACAT1||acetyl-CoA acetyltransferase 1; also called mitochondrial acetoacetyl-CoA thiolase; involved in ketone body synthesis (see below) in the liver; located on chromosome 11q22.3 spanning 27 kb composed of 12 exons encoding a 427 amino acid protein; the protein encoded by the SOAT1 gene (sterol O-acyltransferase 1) was originally referred to as acyl-CoA: cholesterol acyltransferase 1, ACAT1 but due to the nomenclature conflict is no longer designated with this acronym|
|ACAT2||acetyl-CoA acetyltransferase 2; also called cytosolic acetoacetyl-CoA thiolase; involved in cholesterol biosynthesis and in the utilization of ketone bodies by the brain, cardiac muscle, and several other tissues; located on chromosome 6q25.3 and is composed of 10 exons that generate two alternatively spliced mRNAs encoding two isoforms of the enzyme (isoform 1 is amino 397 acids, isoform 2 is 426 amino acids); the protein encoded by the SOAT2 gene (sterol O-acyltransferase 2) was originally referred to as acyl-CoA: cholesterol acyltransferase 2, ACAT2 but due to the nomenclature conflict is no longer designated with this acronym|
|HADHB||hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase, beta subunit; 3-ketoacyl-CoA thiolase; β-ketothiolase; HADHB encodes the β-subunit of mitochondrial trifunctional protein (MTP); located on chromosome 2p23.3 composed of 17 exons that generate three alternatively spliced mRNAs each of which encode a distinct protein isoform|
Each round of β-oxidation produces one mole of FADH2, one mole of NADH, and one mole of acetyl-CoA. The acetyl-CoA, the end product of each round of β-oxidation, then enters the TCA cycle, where it is further oxidized to CO2 with the concomitant generation of three moles of NADH, one mole of FADH2 and one mole of ATP. The NADH and FADH2 generated during the fat oxidation and acetyl-CoA oxidation in the TCA cycle then can enter the respiratory pathway for the production of ATP via oxidative phosphorylation.
Pathway of Mitochondrial β-Oxidation of Long-Chain Fatty Acids
Pathway of Mitochondrial β-Oxidation of Medium- and Short-Chain Fatty Acids
Energy Yield from Mitochondrial β-Oxidation of Fatty Acids
The oxidation of fatty acids yields significantly more energy per carbon atom than does the oxidation of carbohydrates. The net result of the oxidation of one mole of oleic acid (an 18-carbon fatty acid) will be 146 moles of ATP (2 mole equivalents are used during the activation of the fatty acid), as compared with 114 moles from an equivalent number of glucose carbon atoms.
β-Oxidation of Fatty Acids with Odd Numbers of Carbon Atoms
The majority of natural animal derived fatty acids contain an even number of carbon atoms. Fatty acids with an odd number of carbon atoms (odd-chain fatty acids, OCFA) are primarily found in the fat and milk of ruminant animals with a small proportion of plant derived fatty acids being OCFA. Upon complete β-oxidation OCFA there results a single mole of propionyl-CoA. The propionyl-CoA is converted, via a mitochondrially-localized three reaction ATP-dependent pathway, to succinyl-CoA. The succinyl-CoA can then enter the TCA cycle for further oxidation.
The enzymes required for this conversion are propionyl-CoA carboxylase, methylmalonyl-CoA epimerase, and methylmalonyl-CoA mutase, respectively. Propionyl-CoA carboxylase is called an ABC enzyme due to the requirements for ATP, Biotin, and CO2 for the reaction. The clinical significance of methylmalonyl-CoA mutase in this pathway is that it is one of only two enzymes that requires a vitamin B12-derived co-factor for activity. The other B12-requiring enzyme is methionine synthase (see the Amino Acid Metabolism page). This same propionyl-CoA conversion pathway is required for the metabolism of the amino acids valine, methionine, isoleucine, and threonine. For this reason this three-step reaction pathway is often remembered by the mnemonic as the VOMIT pathway, where V stands for valine, O for odd-chain fatty acids, M for methionine, I for isoleucine, and T for threonine.
Propionyl-CoA carboxylase functions as a heterododecameric enzyme (subunit composition: α6β6) and the two different subunits are encoded by the PCCA and PCCB genes, respectively. The biotin-dependent carboxylating enzymes in mammals are multifunctional and contain three distinct enzymatic activities that may be contained in a single protein or in different subunits of the multisubunit enzymes. These three enzymatic activities are the biotin carboxylase (BC), the carboxyltransferase (CT), and the biotin carboxyl carrier protein (BCCP) activities. The α-subunit of propionyl-CoA carboxylase contains the these activities of a typical biotin-dependent carboxylase. The BC domain of the α-subunit resides in the N-terminal region and the BCCP domain resides in the C-terminal region. Propionyl-CoA carboxylase has a domain, called the biotin transfer (BT) domain, that is not found in the other biotin-dependent carboxylase family enzymes. The BT domain is found in the middle of the α-subunit and is required for interactions between the α- and β-subunits.
The PCCA gene is located on chromosome 13q32.3 and is composed of 32 exons that generate eleven alternatively spliced mRNAs, each of which encode a unique protein isoform. The PCCB gene is located on chromosome 3q22.3 and is composed of 17 exons that generate two alternatively spliced mRNAs encoding precursor proteins of 539 amino acids (isoform 1) and 559 amino acids (isoform 2).
Methylmalonyl-CoA epimerase is encoded by the MCEE gene located on chromosome 2p13.3 and is composed of 4 exons that encode a 176 amino acid precursor protein.
Methylmalonyl-CoA mutase is encoded by the MMUT gene located on chromosome 6p12.3 and is composed of 13 exons that encode a precursor protein of 750 amino acids. Mutations in the MMUT gene are one cause of the methylmalonic acidemias.
Mutations in either the PCCA or PCCB gene are associated with propionic acidemia associated with severe ketoacidosis. The original identification of a child suffering from propionyl-CoA deficiency was in 1961. This child suffered frequent episodes of severe ketoacidosis, all of which were precipitated by protein ingestion. Blood and urine analysis demonstrated marked elevations in glycine levels. These initial laboratory studies lead to the disorder being called ketotic hyperglycinemia. However, there is no defect in glycine metabolism with inherited mutations in PCCA or PCCB. The clinical hallmark of the disease is severe ketoacidosis of an episodic nature precipitated primarily due to intake of protein.
Unsaturated Fatty Acid β-Oxidation
The mitochondrial oxidation of unsaturated fatty acids is essentially the same process as for saturated fats, except when a double bond is encountered. In such a case, the bond is isomerized by a specific enoyl-CoA isomerase and oxidation continues. The isomerase, encoded by the enoyl-CoA delta isomerase 1 (ECI1) gene, catalyzes the transformation of 3-cis and 3-trans-enoyl-CoA esters that are the result of the mitochondrial β-oxidation of cis-, mono-, and polyunsaturated fatty acids. The products of the isomerase are the 2-trans-enoyl-CoA intermediates. The ECI1 gene is located on chromosome 16p13.3 and is composed of 7 exons that generate two alternatively spliced mRNAs, both of which encode distinct precursor proteins.
In the case of polyunsaturated fatty acids (PUFA), such as linoleate, the presence of the Δ12 unsaturation results in the formation of a dienoyl-CoA during oxidation. These dienoyl-CoA molecules are substrates for an additional oxidizing enzyme, the NADPH requiring 2,4-dienoyl-CoA reductase which is encoded by the DECR1 gene. The DECR1 gene is located on chromosome 8q21.3 and is composed of 13 exons that generate two alternatively spliced mRNAs, both of which encode distinct precursor proteins.
Because the DECR1 encoded enzyme is localized to the mitochondria and requires NADPH as a co-factor its activity is dependent upon the enzymatic conversion of NAD+ to NADP+. The phosphorylation of NAD+ in the mitochondria is catalyzed by one of the two NAD kinases, specifically the kinase encoded by the NADK2 gene. Loss of function of the NADK2 gene results in loss of mitochondrial NADPH production and as a consequence reduced activity of 2,4-dienoyl-CoA reductase. This rare autosomal disorder is aptly called 2,4-dienoyl-CoA reductase deficiency. Affected individuals exhibit a variable phenotype dependent upon the type of mutation in the NADK2 gene. Symptoms of 2,4-dienoyl-CoA reductase deficiency range from severe neurologic and metabolic dysfunction beginning in early infancy to more subtle symptoms such as childhood-onset optic atrophy or intermittent muscle weakness. In the most severe cases patients have elevated serum levels of C10:2-carnitine. Biochemical analysis in 2,4-dienoyl-CoA reductase deficiency patients will show hyperlysinemia due to the requirement for NADPH of the mitochondrial lysine catabolic enzyme, α-aminoadipate-6-semialdehyde synthase that is encoded by the AASS gene.
Peroxisomal (beta) β-Oxidation Reactions
In addition to mitochondrial oxidation of fatty acids, the peroxisomes also play an important role in overall fatty acid metabolism. Very-long-chain fatty acids (VLCFAs: C18–C26) are preferentially oxidized in the peroxisomes with cerotic acid (a 26:0 fatty acid) being solely oxidized in this organelle. Peroxisomal fatty acid oxidation does not proceed to CO2 and H2O as in the mitochondria. The chain-shortened fatty acyl-CoAs, or carnitine esters, are transported out of the peroxisomes and taken up by the mitochondria where their complete oxidation takes place. The peroxisomes also metabolize di– and trihydroxycholestanoic acids (bile acid intermediates); long-chain dicarboxylic acids that are produced by ω-oxidation of long-chain monocarboxylic acids; pristanic acid via the α-oxidation pathway (see below); certain polyunsaturated fatty acids (PUFAs) such as tetracosahexaenoic acid (24:6), which by β-oxidation yields the important PUFA docosahexaenoic acid (DHA); and certain prostaglandins and leukotrienes.
The enzymatic processes of peroxisomal β-oxidation are very similar to those of mitochondrial fatty acid β-oxidation with one major difference. During mitochondrial fatty acid β-oxidation the first oxidation step, catalyzed by various acyl-CoA dehydrogenases, results in the reduced electron carrier FADH2 that then delivers its’ electrons directly to the electron transport chain for synthesis of ATP. In the peroxisome the first oxidation step is catalyzed by acyl-CoA oxidases which are coupled to the reduction of O2 to hydrogen peroxide (H2O2). Thus, the reaction is not coupled to energy production but instead yields a significant reactive oxygen species (ROS). Peroxisomes contain the enzyme catalase that degrades the hydrogen peroxide back to O2.
Humans contain three peroxisomal acyl-CoA oxidases, ACOX1, ACOX2 and ACOX3. Human and rodent ACOX1 (also referred to as palmitoyl-CoA oxidase) is responsible for the oxidation of straight-chain mono- and dicarboxylic fatty acids, very long-chain fatty acids, prostaglandins, and xenobiotics. In humans, in contrast to rodents, 2-methyl branched fatty acids (primarily pristanoic acid) and the bile acid intermediates, di- and tri-hydroxycoprostanic acids, are desaturated in the peroxisomes by a single enzyme ACOX2 (also called branched-chain acyl-CoA oxidase). The human genome contains an ACOX3 gene but expression from the gene is detected in normal tissue only at extremely low levels. Rodent ACOX3 (also referred to as pristanoyl-CoA oxidase) is the oxidase responsible for oxidation of 2-methy branched chain fatty acids in these animals.
The hydration step and second oxidation step in peroxisomal β-oxidation is carried out by a single bifunctional enzyme as opposed to two separate enzymes. There are two distinct bifunctional enzymes identified as L-bifunctional protein (LBP) and D-bifunctional protein (DBP). LBP is specific for L-3-hydroxyacyl-CoAs and DBP is specific for D-3-hydroxyacyl-CoAs. These bifunctional enzymes are also referred to as multifunctional proteins 1 and 2 (MFP-1 and -2) or L- and D-peroxisomal bifunctional enzymes (L-PBE and D-PBE). The DBP protein is encoded by the hydroxysteroid 17-β dehydrogenase 4 (HSD17B4) gene which is located on chromosome 5q23.1 and is composed of 25 exons that generate five alternatively spliced mRNAs, each of which encode distinct protein isoforms. The LBP protein is encoded by the enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase (EHHADH) gene which is located on chromosome 3q27.2 and is composed of 8 exons that generate two alternatively spliced mRNAs encoding two distinct protein isoforms.
DBP is the primary, if not exclusive enzyme involved in the oxidation of VLCFAs, pristanic acid, and di- and trihydroxycholestanoic acids. The precise role of LBP in human peroxisomal lipid oxidation is unclear. Human peroxisomes contain the thiolase, acetyl-CoA C-acyltransferase 1 (ACAA1), that catalyzes the terminal step in the peroxisomal β-oxidation pathway.
The clinical significance of the activity of the acyl-CoA oxidases of peroxisomal β-oxidation is related to tissue specific oxidation processes. In the pancreatic β-cell there is little, if any, catalase expressed so that peroxisomal oxidation of VLCFAs results in an increased release of ROS that can damage the β-cell contributing to the progressive insulin deficiency seen in obesity.
Microsomal (omega) ω-Oxidation Reactions
The microsomal (endoplasmic reticulum, ER) pathway of fatty acid ω-oxidation represents a minor pathway of overall fatty acid oxidation. However, in certain pathophysiological states, such as diabetes, chronic alcohol consumption, and starvation, the ω-oxidation pathway may provide an effective means for the elimination of toxic levels of free fatty acids. The pathway refers to the fact that fatty acids first undergo a hydroxylation step at the terminal (omega, ω) carbon. Human ω-hydroxylases are all members of the cytochrome P450 (CYP) family of enzymes. These enzymes are abundant in the liver and kidneys.
Specifically, it is members of the CYP4A and CYP4F families that preferentially hydroxylate the terminal methyl group of C10–C26 length fatty acids. CYP4A11 is the human homolog of the rat liver CYP4A1 gene whose encoded enzyme was the first ω-hydroxylase characterized. CYP4A11 utilizes NADPH and O2 to introduce an alcohol to ω-CH3– of several fatty acids including lauric (12:0), myristic (14:0), palmitic (16:0), oleic (18:1) and arachidonic acid (20:4). Following addition of the ω-hydroxyl the fatty acid is a substrate for alcohol dehydrogenase (ADH) which generates an oxo-fatty acid, followed by generation of the corresponding dicarboxylic acid via the action of aldehyde dehydrogenases (ALDH). Further metabolism then takes place via the β-oxidation pathway in peroxisomes.
Another human CYP4A subfamily member has been identified and designated CYP4A22. This protein is highly homologous with CYP4A11 and has been shown to exhibit lauric acid ω-hydroxylase activity. Expression of CYP4A22 is low in all tissue in which it is found. The CYP4A subfamily is not the only CYP4 family of proteins that have been found to possess ω-hydroxylase activity. The CYP4F family enzyme CYP4F3A, which is expressed in leukocytes, is necessary for the ω-hydroxylation and subsequent degradation of leukotriene B4 (LTB4). LTB4 plays an important role in the modulation of inflammatory processes. The CYP4F3 gene is subject to alternative promoter usage and tissue-specific alternative mRNA splicing, which results in two different proteins being produced. These two enzymes are designated CYP4F3A and CYP4F3B, with the latter enzyme being expressed in the liver. CYP4F3B has higher affinity for arachidonic acid.
Another CYP4F family member, identified as CYP4F2, has been identified that also has LTB4-hydroxylating activity. This CYP4F2 protein has a high degree of homology to the CYP4F3B protein and is expressed in the liver and kidneys. CYP4F2 has been shown to be the major arachidonic acid ω-hydroxylase in human liver and kidney. Indeed, the substrate specificity of CYP4F2 for arachidonic acid is much higher than that of CYP4A11 which was originally described as a significant arachidonic acid β-hydroxylase. The formation of ω-hydroxylated arachidonic acid (20-hydroxyeicosatetraenoic acid, 20-HETE) by CYP4A11 plays an important role in the regulation of the cardiovascular system because 20-HETE is a known vasoconstrictor. Polymorphisms in the CYP4A11 gene are associated with hypertension in certain population, particular Asian populations. In addition to ω-hydroxylation of arachidonic acid and LTB4, CYP4F2 has been shown to be responsible for the ω-hydroxylation of the phytyl tail of the tocopherols and tocotrienols (collectively known as vitamin E). Metabolism of vitamin E requires an initial ω-hydroxylation step followed by subsequent β-oxidation.
Additional members of the CYP4F subfamily have been identified in humans. These genes are designated CYP4F8, CYP4F11, and CYP4F12. CYP4F8 is present in epithelial linings and catalyzes the (ω-1)-hydroxylation of prostaglandin H2 (PGH2). CYP4F11 is primarily expressed in liver, but also found in kidney, heart, brain and skeletal muscle. The primary endogenous substrates for CYP4F11 are long-chain 3-hydroxydicarboxylic acids (3-OHDCAs) and the enzyme is also very active at hydroxylating various xenobiotics. CYP4F12 is expressed liver, heart, gastrointestinal and urogenital epithelia and its primary substrates are eicosanoids and xenobiotics.
Phytanic Acid (alpha) α-Oxidation Reactions
Phytanic acid (3,7,11,15-tetramethylhexadecanoic acid) is a fatty acid present in the tissues of ruminants, certain fishes, and in dairy products and is, therefore, an important dietary component of fatty acid intake. Because phytanic acid is a 3-methyl branched fatty acid, it cannot act as a substrate for any of the first enzymes of the mitochondrial β-oxidation pathway (the acyl-CoA dehydrogenases). Phytanic acid is first converted to its CoA-ester and then phytanoyl-CoA serves as a substrate in an α-oxidation process. The α-oxidation reaction (as well as the remainder of the reactions of phytanic acid oxidation) occurs within the peroxisomes and requires a specific α-hydroxylase (specifically phytanoyl-CoA hydroxylase, PhyH), which adds a hydroxyl group to the α-carbon of phytanic acid. PhyH is also called phytanoyl-CoA 2-hydroxylase or phytanoyl-CoA dioxygenase. The PhyH enzyme is derived from the PHYH gene located of chromosome 10p13 that is composed of 10 exons that generate two alternatively spliced mRNAs. The shorter of the two mRNAs encodes the longer 338 amino acid enzyme.
Following two more reactions, the resulting product of phytanic acid metabolism is the 19-carbon fatty acid, pristanic acid (2,6,10,14-tetramethylpentadecanoic acid). Pristanic acid then serves as a substrate for the peroxisomal process of β-oxidation. Because the first step in phytanic acid oxidation involves an α-oxidation step, the process is termed α-oxidation. For more details on peroxisome function see the Refsum disease page. After three steps of peroxisomal β-oxidation, the medium-chain fatty acid product (4,8-dimethylnonanoic acid) is esterified to carnitine and transferred to the mitochondria for further oxidation in the mitochondrial β-oxidation pathway.
Regulation of Fatty Acid Metabolism
In order to understand how the synthesis and degradation of fats needs to be exquisitely regulated, one must consider the energy requirements of the organism as a whole. The blood is the carrier of triglycerides in the form of VLDLs and chylomicrons, fatty acids bound to albumin, amino acids, lactate, ketone bodies and glucose. The pancreas is the primary organ involved in sensing the organism’s dietary and energetic states by monitoring glucose concentrations in the blood. Low blood glucose stimulates the secretion of glucagon, whereas, elevated blood glucose calls for the secretion of insulin.
The metabolism of fat is regulated by two distinct mechanisms. One is short-term regulation, which can come about through events such as substrate availability, allosteric effectors and/or enzyme modification. The other mechanism, long-term regulation, is achieved by alteration of the rate of enzyme synthesis and turn-over.
Fat metabolism can also be regulated by malonyl-CoA-mediated inhibition of CPT-1. Such regulation serves to prevent de novo synthesized fatty acids from entering the mitochondria and being oxidized. The predominant source of the malonyl-CoA that inhibits CPT-1 is from the ACC2 enzyme.
Regulation of ACC1 and ACC2
ACC is the rate-limiting (committed) step in fatty acid synthesis. There are two major isoforms of ACC in mammalian tissues. These are identified as ACC1 and ACC2. ACC1 is strictly cytosolic and is enriched in liver, adipose tissue and lactating mammary tissue. ACC2 was originally discovered in rat heart but is also expressed in liver and skeletal muscle. ACC2 has an N-terminal extension that contains a mitochondrial targeting motif and is found associated with CPT-1 allowing for rapid regulation of CPT-1 by the malonyl-CoA produced by ACC2. Both isoforms of ACC are allosterically activated by citrate and inhibited by palmitoyl-CoA and other short- and long-chain fatty acyl-CoAs. Citrate triggers the polymerization of ACC1 which leads to significant increases in its activity. Although ACC2 does oligomerization similar to that of ACC1, it does not appear to occur to the extent of that of ACC presumably due to its mitochondrial association. However, ACC2 is also allosterically activated by citrate. Glutamate and other dicarboxylic acids can also allosterically activate both ACC isoforms.
ACC activity can also be affected by phosphorylation. Both ACC1 and ACC2 contain at least eight sites that undergo phosphorylation. The sites of phosphorylation in ACC2 have not been as extensively studied as those in ACC1. Phosphorylation of ACC1 at three serine residues (S79, S1200, and S1215) by AMPK leads to inhibition of the enzyme. AMPK-mediated phosphorylation of Ser79 appears to be the most significant for the regulation of ACC1 activity. Glucagon-stimulated increases in cAMP, and subsequently to increased PKA activity, also lead to phosphorylation of ACC. ACC2 is a better substrate for PKA than is ACC1. The activating effects of insulin on ACC are complex and not completely resolved. It is known that insulin leads to the dephosphorylation of the serines in ACC1 that are AMPK targets in the heart enzyme. This insulin-mediated effect has not been observed in hepatocytes or adipose tissues cells. At least a portion of the activating effects of insulin are related to changes in cAMP levels. Activation of α1-adrenergic receptors in liver and skeletal muscle cells inhibits ACC activity as a result of phosphorylation by an as yet undetermined kinase.
Insulin, a product of the well-fed state, stimulates ACC1 and FAS synthesis, whereas starvation leads to a decrease in the synthesis of these enzymes. Adipose tissue levels of lipoprotein lipase also are increased by insulin and decreased by starvation. However, the effects of insulin and starvation on lipoprotein lipase in the heart are just the inverse of those in adipose tissue. This sensitivity allows the heart to absorb any available fatty acids in the blood in order to oxidize them for energy production. Starvation also leads to increases in the levels of cardiac enzymes of fatty acid oxidation, and to decreases in FAS and related enzymes of fatty acid synthesis.
The activity of ACC2 is also regulated by hydroxylation, a modification that enhances its activity. One of the prolyl hydroxylase domain (PHD) family enzymes has been shown to modify the activity of ACC2. The PHD enzymes are 2-oxoglutarate and Fe2+ dependent enzymes whose roles in the regulation of cellular responses to hypoxia have been well studied. With respect to ACC2, the PHD3 enzyme has been shown to be responsible for hydroxylation of the enzyme. In contrast to the phosphorylation of ACC2 by AMPK during energy-deficient states, hydroxylation of ACC2 increases under conditions of high glucose content, in particular in skeletal muscle. When ACC2 is phosphorylated the interaction with PHD3 is impaired.
Regulation of Hormone Sensitive Lipase
Adipose tissue contains hormone-sensitive lipase (HSL), which is activated by PKA-dependent phosphorylation; this activation increases the release of fatty acids into the blood. This in turn leads to the increased oxidation of fatty acids in other tissues such as muscle and liver. In the liver, the net result (due to increased acetyl-CoA levels) is the production of ketone bodies (see below). This would occur under conditions in which the carbohydrate stores and gluconeogenic precursors available in the liver are not sufficient to allow increased glucose production. The increased levels of fatty acid that become available in response to glucagon or epinephrine are assured of being completely oxidized, because PKA also phosphorylates ACC1; the synthesis of fatty acid is thereby inhibited.
The activity of HSL is also affected via phosphorylation by AMPK. In this case the phosphorylation inhibits the enzyme. Inhibition of HSL by AMPK may seem paradoxical since the release of fatty acids stored in triglycerides would seem necessary to promote the production of ATP via fatty acid oxidation and the major function of AMPK is to shift cells to ATP production from ATP consumption. This paradigm can be explained if one considers that if the fatty acids that are released from triglycerides are not consumed they will be recycled back into triglycerides at the expense of ATP consumption. Thus, it has been proposed that inhibition of HSL by AMPK mediated-phosphorylation is a mechanism to ensure that the rate of fatty acid release does not exceed the rate at which they are utilized either by export or oxidation.
Insulin has the opposite effect to glucagon and epinephrine: it increases the synthesis of triglycerides (and glycogen). One of the many effects of insulin is to lower cAMP levels, which leads to increased dephosphorylation through the enhanced activity of protein phosphatases such as PP-1. With respect to fatty acid metabolism, this yields dephosphorylated and inactive hormone-sensitive lipase. Insulin also stimulates certain phosphorylation events. This occurs through activation of several cAMP-independent kinases.
The Glucose-Fatty Acid Cycle
The glucose-fatty acid cycle describes interrelationships of glucose and fatty acid oxidation as defined by fuel flux and fuel selection by various organs. This cycle is not a metabolic cycle such as can be defined by the TCA cycle as an example, but defines the dynamic interactions between these two major energy substrate pools. The glucose-fatty acid cycle was first proposed by Philip Randle and co-workers in 1963 and is, therefore, sometimes referred to as the Randle cycle or Randle hypothesis. The cycle describes how nutrients in the diet can fine-tune metabolic processes on top of the more coarse control exerted by various peptide and steroid hormones. The underlying theme of the glucose-fatty acid cycle is that the utilization of one nutrient (e.g. glucose) directly inhibits the use of the other (in this case fatty acids) without hormonal mediation. The general interrelationships between glucose and fatty acid utilization in skeletal muscle and adipose tissue that constitutes the glucose-fatty acid cycle are diagrammed in the Figure below.
How do the dynamics of the glucose-fatty acid cycle play out under various physiological conditions and changing fuel substrate pools? In the fasted state it is imperative that glucose be spared so that the brain can have adequate access to this vital fuel. Under these conditions, hormonal signals from the pancreas, in the form of glucagon, stimulate adipose tissue lipolysis releasing free fatty acids (FFAs) to the blood for use as a fuel by other peripheral tissues. When the released FFAs enter the liver they oxidized and also serve as substrates for ketogenesis. The oxidation of fatty acids inhibits glucose oxidation as outlined in the above figure. In addition to sparing glucose for the brain, fatty acid oxidation also preserves pyruvate and lactate which are important gluconeogenesis substrates. The effects of fatty acids on glucose utilization can also be observed in the well fed state after a high fat meal and during periods of exercise.
As outlined in the above Figure, the inhibition of glucose utilization by fatty acid oxidation is mediated by short-term effects on several steps of overall glycolysis that include glucose uptake, glucose phosphorylation and pyruvate oxidation. During fatty acid oxidation the resultant acetyl-CoA allosterically activates PDKs that phosphorylate and inhibit the PDHc. PDKs are also activated by increasing levels of NADH that will be the result of increased fatty acid oxidation. Thus, two products of fat oxidation result in inhibition of the PDHc. In addition, excess acetyl-CoA is transported to the cytosol either as citrate (as diagrammed in the Fatty Acid, Triglyceride, and Phospholipid Synthesis page) or as acetylcarnitine. Mitochondrial acetylcarnitine is formed through the action of carnitine O-acetyltransferase (CAT: encoded by the CRAT gene). The CRAT gene is located on chromosome 9q34.11 and is composed of 18 exons that generate seven alternatively spliced mRNAs that collectively encode six distinct protein isoforms. One of the CAT proteins is localized to the mitochondria, one to the peroxisomes, and one is found in the cytosol.
Acetyl-carnitine is transported out of the the mitochondria via the action of carnitine-acylcarnitine translocase (CACT: encoded by the SLC25A20 gene). Once in the cytosol acetyl-carnitine is converted to acetyl-CoA via the action of cytosolic CAT. In the cytosol, citrate serves as an allosteric inhibitor of PFK1 thus limiting entry of glucose into glycolysis. The increase in glucose-6-phosphate that results from inhibition of PFK1 leads to feed-back inhibition of hexokinase which in turn limits glucose uptake via GLUT4. Additional mechanisms of fatty acid metabolism that lead to interference in glucose uptake and utilization are the result of impaired insulin receptor signaling. These latter processes are discussed in detail in the Insulin Function page.
Mechanisms by which glucose utilization inhibits fatty acid oxidation are tissue specific due primarily to the differences in Km of hepatic glucokinase and skeletal muscle and adipose tissue hexokinase. In addition, hepatic CPT-1 is approximately 100-fold less sensitive to inhibition by malonyl-CoA than are the skeletal muscle and cardiac isoforms. When glucose is oxidized in glycolysis the resultant pyruvate enters the mitochondria via the pyruvate symporter. Increasing mitochondrial pyruvate inhibits the PDKs allowing for rapid decarboxylation of pyruvate by the PDHc ensuring continued entry of glucose into the glycolytic stream. Some of the acetyl-CoA derived from pyruvate oxidation will be diverted from the TCA cycle as citrate and transported to the cytosol by the tricarboxylic acid transporter (TCAT). The citrate is converted to acetyl-CoA and oxaloacetate by ATP-citrate lyase (ACLY) and can now serve as a substrate for ACC. The resultant malonyl-CoA will inhibit CPT-1 thus, restricting mitochondrial uptake and oxidation of fatty acyl-CoAs. The inhibition of fatty acid oxidation in the liver re-routes LCFAs into triglycerides (TAGs). Long term effects of excess glucose are reflected in hepatic steatosis resulting from the diversion of fats into TAGs instead of being oxidized.
In addition to being regulated by intermediates of glucose and fat oxidation, several enzymes in these two pathways are regulated at the level of post-translational modification and/or gene expression. Most of these regulatory schemes have been covered in the above sections.
Clinical Significance of Defects in Fatty Acid Metabolism
The majority of clinical problems related to fatty acid metabolism are associated with the processes of mitochondrial fatty acid β-oxidation but also include disorders in peroxisomal lipid metabolism. Disorders that result from defects in mitochondrial fatty acid β-oxidation fall into three main groups:
Deficiencies in Carnitine
Deficiencies in carnitine can be either primary or secondary. Primary carnitine deficiencies are due to defects in carnitine transport into cells or due to defects in synthesis from lysine. Mutations in the major carnitine transporter, encoded by the SLC22A5 gene (also known as zwitterion/cation transporter 2 (OCTN2), is the predominant cause of primary carnitine deficiency (correctly identified as carnitine deficiency, systemic primary).
Secondary carnitine deficiencies are most commonly the result of trapping in fatty acylcarnitines due to defects in mitochondrial fatty acid oxidation enzymes.
Carnitine deficiencies lead to an inability to transport long-chain fatty acids into the mitochondria for oxidation. Carnitine deficiencies can occur in newborns and particularly in pre-term infants. Carnitine deficiencies also are found in patients undergoing hemodialysis or those affected by any one of various organic acidemias/acidurias (e.g. propionic acidemia or isovaleric acidemia).
Carnitine deficiencies may manifest with systemic symptomology or may be limited to only muscles. Symptoms can range from mild occasional muscle cramping to severe weakness or even death. Treatment is by oral carnitine administration.
Carnitine Palmitoyltransferase Deficiencies
Deficiencies in CPT-1 are relatively rare and affect primarily the liver and lead to reduced fatty acid oxidation and ketogenesis. The most common symptom associated with CPT-1 deficiency is hypoketotic hypoglycemia associated with hepatic pathology. There is also an elevation in blood levels of carnitine. The liver involvement results in hepatomegaly and the muscle involvement results in weakness.
CPT-2 deficiencies can be classified into three main forms. The adult form is the most common and affects primarily the skeletal muscles and is called the adult myopathic form. This form of the disease causes muscle pain and fatigue and myoglobinuria following prolonged exercise. This form of CPT-2 deficiency manifest with symptoms that are very similar to those exhibited by patients with the glycogen storage disease, McArdle disease. However, with McArdle disease the muscle pain and cramping is associated with short bursts of aerobic exercise, such as following sprinting, as opposed to following sustained exercise as in the case of CPT-2 deficiency.
The severe infantile multisystem form manifests in the first 6–24 months of life with most afflicted infants demonstrating significant involvement before 1 year. The primary symptom of this form of CPT-2 deficiency is hypoketotic hypoglycemia. Symptoms will progress to severe hepatomegaly and cardiomyopathy. Often times death from CPT-2 deficiency may be misdiagnosed as sudden infant death syndrome, SIDS.
The rarest form of CPT-2 deficiency is referred to as the neonatal lethal form. Symptoms of this form appear within hours to four days after birth and include respiratory failure, hepatomegaly, seizures, hypoglycemia, and cardiomegaly. The cardiomegaly will lead to fatal arrhythmias.
Carnitine acyltransferases may also be inhibited by sulfonylurea drugs, such as tolbutamide and glyburide, that are used in the treatment of the hyperglycemia of type 2 diabetes.
Carnitine Acylcarnitine Translocase Deficiency
Mutations in the SLC25A20 gene that encodes the carnitine acylcarnitine translocase (CACT) are associated with a rare autosomal recessive disorder. Carnitine acylcarnitine translocase deficiency manifests in the neonatal period (within hours of birth) with breathing difficulty, irregular heart beat, and seizures. Metabolic consequences of CACT deficiency are hypoketotic hypoglycemia, dicarboxylic aciduria, elevated serum levels of long-chain acylcarnitines, reduced serum carnitine, and hyperammonemia.
Deficiencies in Acyl-CoA Dehydrogenases
The acyl-CoA dehydrogenase deficiency disorders represent a group of inherited disorders that are associated with impairment of mitochondrial fatty acid β-oxidation. As the name implies, these disorders result from deficiencies in the family of acyl-CoA dehydrogenases that catalyze the first reaction in the mitochondrial β-oxidation pathway. The enzymes affected belong to one of three categories:
- Very long-chain acyl-CoA dehydrogenase (VLCAD): The symptoms that result from deficiencies in VLCAD were originally ascribed to loss of long-chain acyl-CoA dehydrogenase (LCAD) activity. However, expression of the gene encoding LCAD (ACADL) is poor in humans and, therefore, LCAD does not contribute, to any significant extent, to long-chain fatty acid oxidation. Mitochondrial oxidation of long-chain fatty acids begins through the activity of VLCAD.
- Medium-chain acyl-CoA dehydrogenase (MCAD): MCAD deficiency (MCADD) is the most common form of acyl-CoA dehydrogenase deficiency. In the first years of life this deficiency will become apparent following a prolonged fasting period. Symptoms include vomiting, lethargy and frequently coma. Excessive urinary excretion of medium-chain dicarboxylic acids as well as their glycine and carnitine esters is diagnostic of this condition. In the case of this enzyme deficiency taking care to avoid prolonged fasting is sufficient to prevent clinical problems.
- Short-chain acyl-CoA dehydrogenase (SCAD)
Mitochondrial Trifunctional Protein (MTP) Deficiency
In addition to deficiencies in the fatty acyl-CoA dehydrogenases, that catalyze the first reaction of mitochondrial fatty acid β-oxidation, deficiencies in one of the activities of the mitochondrial trifunctional protein (MTP), the enzyme complex that catalyzes the last three reactions of mitochondrial long-chain fatty acid oxidation, have also been identified. The MTP is composed of α-subunits and β-subunits encoded by the HADHA and HADHB genes, respectively. Mutations in the gene encoding the α-subunits (HADHA) represent one form of the MTP deficiency syndromes and complete loss of MTP activity represents the other.
The HADHA gene encodes the enzyme activity of the MTP referred to as long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD). As such, mutations in the HADHA gene are commonly referred to as long-chain 3-hydroxyacyl-CoA deficiency. Mutations in the HADHA gene result in phenotypes similar to other disorders in mitochondrial fatty acid β-oxidation such as hypoketotic hypoglycemia. However, LCHAD deficiency is associated with unique symptoms that include progressive pigmentary retinopathy and progressive peripheral neuropathy. Total loss of MTP activity is often associated with a very high rate of early lethality. However, some patients with total MTP deficiency have been reported that exhibit a much less severe phenotype, with peripheral neuropathy being the only prominent symptom.
Lipid Storage Myopathies (LSM)
The lipid storage myopathies (LSM) represent a heterogeneous group of inherited disorders that, in addition to other pathologies, are all characterized by abnormal lipid accumulation in muscle fiber. The LSM are classified based upon pathological findings which result in large part due to the accumulation of lipid droplets (LD) in muscle but also in other tissues. Four discernable LSM have been categorized and includes the above indicated primary carnitine deficiencies (PCD), multiple acyl-CoA dehydrogenase deficiency (MADD; also known as glutaric acidemia type II, GAII), and the neutral lipid storage diseases (NLSD) which includes NLSD type M (NLSDM) and NLSD type I (NLSDI). The lipid myopathies also include several of the diseases indicated above such as VLCAD, MCAD, and SCAD deficiencies, CPT-2 deficiency, and the mitochondrial trifunctional protein (MTP) deficiencies.
Other lipid myopathies have been shown to be the result of lipin 1 (phosphatidic acid phosphatase) deficiency, acyl-CoA dehydrogenase 9 (ACAD9) deficiency, and acetyl-CoA acyltransferase 2 (ACAA2; also known as medium-chain 3-ketoacyl-CoA thiolase, MCKAT) deficiency.
Peroxisomal Fatty Acid Oxidation Defects
Refsum disease is a rare inherited disorder in which patients harbor a defect in the peroxisomal α-oxidizing enzyme, phytanoyl-CoA hydroxylase (PhyH). Although mutations in PhyH are the primary cause of Refsum disease, the syndrome can also result from defects in the peroxisomal protein (PEX7) responsible for the import of PhyH into the peroxisome. Patients accumulate large quantities of phytanic acid in their tissues and serum. This leads to severe symptoms, including cerebellar ataxia, retinitis pigmentosa, nerve deafness and peripheral neuropathy. As expected, the restriction of dairy products and ruminant meat from the diet can ameliorate the symptoms of this disease. It should be noted that accumulation of phytanic acid is not solely the result of defects in PhyH. Phytanic acid accumulation is also seen when there are inherited defects in peroxisome function leading to Zellweger syndrome, neonatal adrenoleukodystrophy and infantile Refsum disease. In addition, rhizomelic chondrodysplasia punctata, type 1 (RCDP1) results in phytanic acid accumulation. Refsum disease due to deficiency in PhyH is properly referred to as classical Refsum disease to distinguish it from infantile Refsum due to peroxisome dysfunction.
Synthesis and Utilization of the Ketones
During high rates of fatty acid oxidation, primarily in the liver, large amounts of acetyl-CoA are generated. Indeed, the major source of acetyl-CoA for hepatic ketone synthesis is from the mitochondrial β-oxidation of fatty acids. However, amino acid oxidation can and does contribute to the pool of available acetyl-CoA. Catabolism of amino acids, where leucine is a major contributor, contributes up to 5% of the acetyl-CoA diverted into ketone synthesis in the liver. The excess acetyl-CoA exceeds the capacity of the TCA cycle, and one result is what has been referred to as a spillover pathway, the synthesis of ketone bodies.
The synthesis of the ketone bodies (ketogenesis) occurs in the mitochondria allowing this process to be intimately coupled to the rate of hepatic fatty acid oxidation. Conversely, the utilization of the ketones (ketolysis) occurs in the cytosol. The ketone bodies are acetoacetate, β-hydroxybutyrate, (BHB) and acetone. The pathways of ketone synthesis and utilization are classically viewed as being required for energy generation during periods of carbohydrate restriction, during fasting, and during a prolonged fast (starvation). However, more recent studies have discovered that ketones are important mediators of metabolic and signal transduction processes when carbohydrates are in abundance.
The formation of acetoacetyl-CoA occurs by condensation of two moles of acetyl-CoA. This reaction is essentially a reversal of the thiolase (HADHB or ACAA2) catalyzed reaction of fatty acid β-oxidation but is in fact catalyzed by the mitochondrial enzyme acetoacetyl-CoA thiolase (encoded by the ACAT1 gene). Acetoacetyl-CoA and an additional acetyl-CoA are converted to β-hydroxy-β-methylglutaryl-CoA (HMG-CoA: 3-hydroxy-3-methylglutaryl-CoA) by mitochondrial HMG-CoA synthase (encoded by the HMGCS2 gene), an enzyme found in large amounts only in the liver and intestinal epithelial cells. The reaction catalyzed by the HMGCS2 encoded enzyme represents the regulated and rate-limiting step in ketone synthesis.
Humans express two HMG-CoA synthase genes, the mitochondrial HMGCS2 gene just described, and the HMGCS1 gene which encodes a cytosolic enzyme that is involved in cholesterol biosynthesis. The HMGCS2 gene is located on chromosome 1p12 and is composed of 10 exons that generate two alternatively spliced mRNAs, both of which encode distinct protein isoforms (isoform 1 is 508 amino acids and isoform 2 is 466 amino acids). Expression of the HMGCS2 gene is positively regulated via glucagon signal transduction events and negatively regulated by insulin signal transduction events (see Regulation of Ketogenesis below).
HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) in the mitochondria is converted to acetoacetate by the action of HMG-CoA lyase. The HMG-CoA lyase gene (HMGCL) is located on chromosome 1p36.11 and is composed of 9 exons that generate two alternatively spliced mRNAs which encode two distinct precursor proteins (isoform 1 is 325 amino acids and isoform 2 is 254 amino acids). HMG-CoA lyase is also involved in catabolism of the amino acid leucine, catalyzing the final step in that pathway.
Mutations in the HMGCL gene result in a disorder referred to as 3-hydroxy-3-methylglutaric aciduria. Inheritance of 3-hydroxy-3-methylglutaric aciduria occurs as an autosomal recessive disorder. Since the enzyme encoded by the HMGCL gene is also involved in leucine catabolism, mutations in HMGCL also result in defects in metabolism of this amino acid and consequently leads to accumulation of leucine metabolites, 3-hydroxy-3-methylglutaric acid, 3-methylglutaconic acid, 3-methylglutaric acid, and 3-hydroxyisovaleric acid. The reduced capacity to synthesize ketone bodies results in inefficient energy production, particularly by the brain, during periods of fasting. Reduced HMG-CoA lyase activity is associated with episodes of hypoglycemia and metabolic acidosis. HMG-CoA lyase deficiency is treatable by diet, particularly leucine restriction, and avoidance of prolonged fasting. Supplementary glucose is administered to prevent hypoglycemia. Without prompt and proper therapeutic intervention, death occurs early in life.
Acetoacetate can undergo spontaneous decarboxylation to acetone, or be enzymatically converted to β-hydroxybutyrate (BHB) through the action of mitochondrial β-hydroxybutyrate dehydrogenase which is encoded by the BDH1 gene. The BDH1 gene is located on chromosome 3q29 and is composed of 19 exons that generate three alternatively spliced mRNAs, each of which encode the same 343 amino acid precursor protein. Functional β-hydroxybutyrate dehydrogenase is a homotetrameric complex.
Humans express a second BDH gene, BDH2, whose encoded protein is only 20% identical to the BDH1 encoded protein. The BDH2 encoded protein appears to play a role in iron homeostasis.
The precise mechanism by which the ketone bodies cross the inner mitochondrial membrane is unclear but may occur by simple diffusion out of the mitochondria of hepatocytes. Once out of the mitochondria the ketone bodies are transported into the blood via the action of the plasma membrane localized monocarboxylate transporter 1 (MCT1) or MCT2 transporters which are encoded by the SLC16A1 and SLC16A7 genes, respectively.
When the level of glycogen in the liver is high the production of β-hydroxybutyrate (BHB) increases. When carbohydrate utilization is low or deficient, the level of oxaloacetate will also be low, resulting in a reduced flux through the TCA cycle. This in turn leads to increased release of ketone bodies from the liver for use as fuel by other tissues. In early stages of starvation (beyond one week without food intake), when the last remnants of readily releasable fat are oxidized, heart and skeletal muscle will consume primarily ketone bodies to preserve glucose for use by the brain and erythrocytes. Eventually the brain will adapt to ketone oxidation for energy in order to preserve what little glucose can be made via gluconeogenesis in a starvation scenario for use by erythrocytes as these cells can get the necessary ATP from no other source. Acetoacetate and predominantly β-hydroxybutyrate (BHB) also serve as major substrates for the biosynthesis of neonatal cerebral lipids.
Once in the circulation the ketones are taken up by non-hepatic tissues most likely by the plasma membrane localized monocarboxylate transporter 1 (MCT1). Evidence for the role of MCT1 in ketone uptake came from the observations that loss-of-function mutations in the SLC16A1 gene (which encodes the MCT1 protein) are associated with spontaneous ketoacidosis.
Both β-hydroxybutyrate and acetoacetate are taken up by the mitochondria of non-hepatic tissues for their reconversion back to acetyl-CoA. Non-hepatic ketone body utilization occurs via a series of mitochondrial reactions (shown in the Figure below) that are essentially a reversal of ketone body synthesis.
The initial steps involve the conversion of β-hydroxybutyrate to acetoacetate and of acetoacetate to acetoacetyl-CoA. The first step in ketone utilization involves the reversal of the β-hydroxybutyrate dehydrogenase reaction. It is important to appreciate that under conditions where tissues are utilizing ketones for energy production their NAD+/NADH ratios are going to be relatively high thus, driving the β-hydroxybutyrate dehydrogenase catalyzed reaction in the direction of acetoacetate synthesis.
The second reaction of ketone utilization involves the action of 3-oxoacid-CoA transferase 1 (encoded by the OXCT1 gene) which is also known as succinyl-CoA:3-oxoacid-CoA transferase (SCOT). The latter enzyme is expressed in all human cells that contain a mitochondria except for hepatocytes. Importantly, the lack of OXCT1 expression in the liver allows the liver to produce ketone bodies but not to utilize them. This ensures that non-hepatic tissues have access to ketone bodies as a fuel source during prolonged fasting and starvation.
The OXCT1 gene is located on chromosome 5p13.1 and is composed of 17 exons that generate six alternatively spliced mRNAs, each of which encode a distinct precursor protein. Cytosolic acetoacetyl-CoA is hydrolyzed into two molecules of acetyl-CoA primarily by the ACAA2 encoded mitochondrial thiolase (see Table above in the section covering mitochondrial β-oxidation). The other two mitochondrial thioloases, encoded by the ACAT1 and HADHB genes, can also hydrolyze acetoacetyl-CoA.
Regulation of Ketogenesis
The fate of the products (acetyl-CoA) of fatty acid metabolism, pyruvate metabolism, and the metabolism of numerous amino acids is determined by an individual’s dietary, physiological, and hormonal status. Although, as indicated, acetyl-CoA can be derived through oxidative metabolism of lipids, carbohydrates, and amino acids, the predominant source of the acetyl-CoA diverted into ketone synthesis in the liver is from fatty acid oxidation. As indicated above, amino acid catabolism, in particular leucine catabolism, contributes around 5% of the total pool of acetyl-CoA for hepatic ketone synthesis. Although carbohydrate and pyruvate catabolism yield acetyl-CoA these reaction are negligible with respect to substrate generation for ketogenesis. The overall rate of hepatic ketogenesis may by affected by several factors:
1. Control in the release of free fatty acids from adipose tissue directly affects the level of ketogenesis in the liver. This is, of course, substrate-level regulation. Fatty acid release from adipose tissue is controlled via the activity of hormone-sensitive lipase (HSL). When glucose levels fall, pancreatic glucagon secretion increases resulting in phosphorylation of adipose tissue HSL, thus resulting in increased hepatic ketogenesis due to increased substrate (free fatty acids) delivery from adipose tissue. Conversely, insulin, released in the well-fed state, inhibits ketogenesis via the triggering of dephosphorylation and inactivation of adipose tissue HSL.
2. Once fats enter the liver, they have two distinct fates. They may be activated to acyl-CoAs and oxidized, or esterified to glycerol in the production of triglycerides. If the liver has sufficient supplies of glycerol-3-phosphate, most of the fats will be turned to the production of triglycerides.
3. The acetyl-CoA generated by the oxidation of fats and amino acids can be completely oxidized in the TCA cycle or it can be diverted into lipid biosynthesis. If the hepatic demand for ATP is high the fate of acetyl-CoA is likely to be further oxidation to CO2. This is especially true under conditions of hepatic stimulation by glucagon which results in increased gluconeogenesis and the energy for this process is derived primarily from the oxidation of fatty acids supplied from adipose tissue.
4. The regulation of the HMGCS2 gene and the encoded enzyme itself are subject to various regulatory processes. Glucagon also directly enhances hepatic ketone synthesis at the level of gene expression. The HMGCS2 gene is transcriptionally activated by the forkhead transcription factor, FOXA2 whose activity is enhanced in response to elevated cAMP levels as occurs via glucagon activation of its receptor. Conversely, the activity of FOXA2 is inhibited by insulin via the insulin receptor-mediated activation of the kinases, phosphatidylinositol-3-kinase (PI3K) and AKT/PKB. The transcription factor PPARα induces the expression of the HMGCS2 gene in the liver in response to the consumption of a ketogenic diet (e.g. high-fat diet) as well as in response to the physiological changes occurring during starvation. The enzymatic activity of HMGCS2 is regulated by both allosteric effectors and by post-translational modifications. Succinyl-CoA allosterically inhibits HMGCS2 and it also serve as a substrate for succinylation of lysine residues in the enzyme. In fact, in addition to HMGCS2, HMG-CoA lyase, and β-hydroxybutyrate dehydrogenase are also subjected to lysine succinylation. When these enzymes are succinylated they are targets for the sirtuin 5 (SIRT5) deacetylase. Humans express seven sirtuin genes that each encode NAD+-dependent enzymes. In contrast to SIRT5-induced inhibition of activity, the action of the SIRT3 deacetylase on HMGCS2 results in enhanced enzyme activity.
5. In addition, glucagon results in phosphorylation and inhibition of acetyl-CoA carboxylase (ACC), the rate limiting enzyme of de novo fatty acid synthesis. Conversely, under conditions of insulin release, hepatic ACC is activated and the excess acetyl-CoA will be converted into malonyl-CoA and then free fatty acids. The increased malonyl-CoA results in inhibition of fatty acid transport into the mitochondria resulting in reduced fat oxidation and reduced production of excess acetyl-CoA.
Metabolic and Clinical Significance of Ketones
The production and utilization of the ketone bodies are interconnected with most aspects of metabolic homeostasis including that of fatty acid oxidation, the TCA cycle, gluconeogenesis, and endogenous lipid and sterol biosynthesis. Synthesis of ketones occurs at a relatively low rate during normal feeding and under conditions of normal physiological status. The normal concentration of total ketone bodies in the circulation of healthy adult humans will exhibit circadian oscillations of between approximately 100μM and 250μM. The level of circulating ketones can rise as high as 1mM after prolonged exercise or following a 24 hr period of fasting. Normal physiological responses to carbohydrate shortages cause the liver to increase the production of ketone bodies from the acetyl-CoA generated from fatty acid oxidation. The human liver produces up to 300 grams of ketone bodies per day and these molecules will contribute to between 5% and 20% of the total body energy expenditure depending upon the fed, fasted, or starved states. During ketotic states both acetoacetate and β-hydroxybutyrate will be excreted in the urine and their levels in the urine will be proportionate to those in the circulation. However, it should be noted that most clinical measurements of urine ketones are only detecting acetoacetate and not β-hydroxybutyrate.
Ketone body oxidation is a significant contributor to overall energy metabolism in humans within extrahepatic tissues, particularly in the brain, under many different physiological states. The principle normal physiological conditions that result in increased ketone utilization are fasting and post-exercise recovery as well as in response to the consumption low carbohydrate diets. During pregnancy and in the neonate the utilization of ketones is also elevated. The most significant disruption in the level of ketosis, leading to profound clinical manifestations, occurs in untreated insulin-dependent diabetes mellitus, type 1 diabetes. This physiological state, diabetic ketoacidosis (DKA), results from a reduced supply of glucose, due to lack of circulating insulin in the absence of therapeutic injection, and a concomitant increase in fatty acid oxidation due, in large part, to an unregulated increase in circulating glucagon. The DKA state can result in circulating ketone bodies being as high as 20mM. The increased production of acetyl-CoA leads to ketone body production that exceeds the ability of peripheral tissues to oxidize them. Ketone bodies are relatively strong acids (pKa around 3.5), and their increase lowers the pH of the blood resulting in significant metabolic acidosis. This acidification of the blood is dangerous for many reasons but in particular because it impairs the ability of hemoglobin to bind oxygen.
Nonoxidative Metabolic Fates of Ketones
Although the primary function of ketones is for energy generation by non-hepatic tissues during periods of fasting (particularly the brain), they can be directed into lipid metabolic pathways within the liver. Acetoacetate can be exported out of the mitochondria for conversion to acetoacetyl-CoA by a cytoplasmic acetoacetyl-CoA synthetase encoded by the AACS gene. The cytoplasmic acetoacetyl-CoA can be hydrolyzed to two molecules of acetyl-CoA by the action of the cytosolic thiolase (acetyl-CoA acetyltransferase 1) encoded by the ACAT1 gene. The resulting cytosolic acetyl-CoA can then be diverted into the synthesis of fatty acids. Cytosolic acetoacetyl-CoA and acetyl-CoA can be directed into the cholesterol biosynthesis pathway via the action of cytosolic HMG-CoA synthase encoded by the HMGCS1 gene.
Colonic bacteria generate short-chain fatty acids (SCFA) through fermentation of soluble fiber. These SCFA include acetate, propionate, and butyrate which are absorbed by colonocytes. Metabolically the gut bacteria-derived SCFA can be used for oxidation or diverted into the ketogenesis pathway. In addition to hepatocytes, gut epithelial cells are the only other cell to express the HMGCS2 gene allowing them to contribute to ketone synthesis. However, gut-derived SCFA also exert other important cell signaling effects. Although the beneficial effects of these SCFA can be attributed to all three, the most extensively studied effects are those exerted by butyrate. Butyrate promotes colonocyte cell differentiation, suppresses colonic inflammation, and of clinical significance it induces cell cycle arrest and apoptosis in colon cancer cells. These beneficial effects of butyrate (and also shown for propionate), within the colon are mediated, in part, by its ability to inhibit the activity of histone deacetylases (HDAC). Like butyrate, the ketone β-hydroxybutyrate (BHB) has also been shown to inhibit the activity of HDAC. The effects of β-hydroxybutyrate-mediated HDAC inhibition are enhanced expression of genes that reduce the level of oxidative stress.
In addition to altering the patterns of gene expression through modification of HDAC activity, β-hydroxybutyrate can alter gene expression patterns by serving as a direct modifier of lysine residues in histones resulting in lysine β-hydroxybutyrylation. The level of histone β-hydroxybutyrylation increases in hepatocytes in response to prolonged fasting. The effects histone β-hydroxybutyrylation on gene expression represents a novel form of epigenetic control. The level of histone β-hydroxybutyrylation is similar to the level of the more well studied epigenetic histone modification, acetylation. The consequences of histone lysine β-hydroxybutyrylation are changes in expression of numerous genes such as the gene for the transcriptional co-activator, PGC-1β (gene symbol: PPARGC1B) which is itself involved in the regulation of expression of numerous genes involved in energy homeostasis, the insulin receptor substrate 2 (IRS2) gene whose encoded protein is involved in insulin signaling, and the carnitine palmitoyltransferase 1A (CPT1) gene whose encoded protein regulates the ability of the mitochondria to oxidize fatty acids.
β-Hydroxybutyrate (BHB) also exerts cell signaling effects by direct binding and activation of the G-protein coupled receptor (GPCR) originally identified as GPR109A. GPR109A is a member of a family of hydroxycarboxylic acid (HCA)-responsive GPCR and as such is now identified as HCA2 (encoded by the HCAR2 gene). Indeed, β-hydroxybutyrate is the only identified endogenous ligand for HCA2. The HCAR2 gene is expressed in both white and brown adipose tissue (WAT and BAT) and in cells of the immune system. HCA2 is a Gi-coupled GPCR and its activation in adipose tissue results in reduced activation of hormone-sensitive lipase, HSL. The activation of HCA2 by β-hydroxybutyrate in adipose tissue, therefore, serves as a negative feed-back loop on adipose tissue lipolysis by reducing the release of free fatty acids from adipocytes. β-Hydroxybutyrate also exerts effects on another GPCR, the free fatty acid receptor 3 (FFAR3; originally identified as GPR41). Interference with FFAR3 signaling by β-hydroxybutyrate has been shown to be responsible for the suppression of sympathetic nervous system activity exerted by β-hydroxybutyrate.